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ABSTRACT

The World Health Organization acknowledges that single-use medical devices
(SUDs) are commonly reprocessed and reused beyond their intended life to deliver
patient care in low-resource settings. SUDs originally intended for use on one patient for
one procedure are “reprocessed” in such cases, which involves cleaning, disinfection or
sterilization, and functional testing before they are reused in hospitals. Studies have
shown that reuse of SUDs in countries where reprocessing is unregulated can be safe if
stringent standard operating procedures are followed.
The broad objective of this thesis was to validate a reprocessing protocol for the
bag-valve-mask (BVM), a single-use device commonly reused in low- and middleincome countries. This device is critical for supporting neonatal resuscitation in low- and
middle-income countries, where neonatal mortality due to failure to establish breathing
has a prevalence of roughly 19%. This was accomplished by documenting reprocessing
practices in a tiered healthcare system in Tanzania and assessing cleaning markers and
functional performance parameters for BVM exposed to a bleach-based reprocessing
protocol under simulated worst-case conditions and by defining human factors affecting
BVM reprocessing.
Tanzanian hospital personnel interviews revealed variations in reprocessing
practices and demonstrated a need for validated reprocessing protocols and screening
methods for single-use devices. The bleach-based protocol was validated to meet
disinfection targets established by the FDA, and its efficacy was unaffected by simulated
worst-case conditions including high organic load, low hypochlorous acid presence (pH
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~11), and prolonged drying of bioburden following simulated use. The BVM met
performance targets even after multiple reprocessing cycles and simulated abrasive wear.
Finally, the usability study defined human factors relevant to user compliance with the
validated bleach-based protocol. This body of work ultimately provides a comprehensive
framework for validating reprocessing protocols for single-use medical devices such as
the BVM. The approaches outlined in this thesis support the safe reuse of medical
devices through reprocessing validation using protocols that are suitable for clinical or
laboratory settings.
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CHAPTER ONE
INTRODUCTION: MEDICAL DEVICE REPROCESSING
1.1 GLOBAL MEDICAL DEVICE REPROCESSING
Global Market Outlook
Reprocessing is a validated process for rendering a medical device fit for reuse [1]
and is FDA-regulated in the United States [2-4]. The global market for medical device
reprocessing was valued at $1.079 billion in 2016 and is forecasted to grow to
approximately $2.4 billion dollars by 2022, experiencing a compound annual growth rate
of 10.6% [5]. The global demand for reprocessing is motivated by three main factors: (1)
reduction in healthcare expenditure, (2) increased medical waste sustainability efforts,
and (3) economic opportunity to enter new markets [5, 6]. Reprocessed devices are
considered substantially equivalent to the original device at roughly half the cost, saving
US hospitals over $250 million a year through third-party reprocessing [5, 6]. The
healthcare sector is the second largest contributor to landfill waste in the US [7]. In the
context of reprocessed single-use medical devices (SUDs), reprocessing can reduce
medical waste in landfills and cut down on red bag (regulated medical waste) disposal
costs, which can be 5 to 10 times more costly than regular waste [5, 6]. Finally, the lower
price of reprocessed devices allows entrance into new markets on a global scale [6]. This
enables access to medical technology for healthcare systems that are unable to support
the expense of the new, original medical device.

1.2 REPROCESSING: A SYSTEMATIC APPROACH
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Reprocessing of Reusable Medical Devices
Reprocessing is a multi-step process that ensures that a clinically used (also
referred to as ‘soiled’ in this document) device is appropriately cleaned, disinfected or
sterilized, and functionally sound before its reuse. This process begins with placing the
used device(s) into a common bin and transporting them to central sterile supply. The
device should be inspected for visible defects or wear, and if damage is present, the
device should be discarded. Next, the device receives cleaning. This step involves
physically removing biological soil and possibly microorganisms (together, this is termed
‘bioburden’). Cleaning may remove pathogenic material in the process, but the primary
goal is to ensure that the device’s internal/external surfaces are free of biological soil so
that the final stage of reprocessing is fully effective. In reality, both of these steps may
happen in tandem or in cycles. Hospital central sterile supply personnel initially may
grossly inspect the devices during manual cleaning and perform a more thorough
inspection with magnifying glasses under bright lights once devices are put through a
washer. This is done in between the “dirty” and “sterile” zones of the room, as devices
are prepared for an important phase, disinfection/sterilization. Following this, the device
is assessed for functionality. Functionality assessments can be performed through a series
of quick tests that evaluate key device functions. After cleaning and functionality tests are
performed, devices are arranged in trays and packaged for sterilization units (if
applicable). Finally, disinfection or sterilization is performed to effectively kill
microorganisms and reduce the risk of infection.
Risk Assessment for Reprocessed Devices
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The Spaulding Classification provides a way of categorizing reprocessed medical
devices based on infection risk [8]. Devices are classified into one of three categories:
non-critical, semi-critical, and critical. Non-critical devices are exposed to topical
surfaces (unbroken skin) and, as a result, have low risk for transmission of infectious
agents to patients. Devices in this category require low-level disinfection. Semi-critical
devices come into contact with mucous membranes but not sterile tissue or cavities.
Devices in this category pose a higher risk of infection (but lower than critical
reprocessed devices) and are free of all microorganisms. However, small numbers of
bacterial spores are permissible. The research in this thesis will focus on reprocessing of
semi-critical devices, which require a 6-log reduction in microorganisms to satisfy highlevel disinfection requirements. Critical devices come into contact with sterile body tissue
and cavities and are therefore at high risk of transmitting infection to the patient should
they be contaminated with microorganisms. Devices in this category require sterilization.
US Regulatory Guidelines
Reprocessing practices vary within global regulatory frameworks for medical
devices [9]. Medical device reprocessing is regulated in the United States, Europe,
Australia and other countries to ensure substantial equivalence of the reprocessed device
to the original unused device [1-2, 10, 11]. One of the most pertinent documents related
to reprocessing of medical devices is the 2002 Medical Device User Fee and
Modernization Act (MDUFMA), which requires reprocessors to submit validation proof
demonstrating their reprocessing procedure was effective in meeting cleaning,
disinfection/sterilization, and functionality targets for the reused device [2].

3

Manufacturers of reusable devices are required to provide appropriate labeling and
thorough instructions for use for reprocessing of the device [2]. The FDA has also issued
guidance documents that address human factors considerations in the validation of
reprocessing protocols and development of medical devices [1, 14], which is utilized in
this body of research.
In addition to this, there are guidance documents addressing the experimental
design for reprocessing validation, which recommend the use of simulated worst-case use
conditions [1, 3, 4]. Simulated worst-case use conditions involve selecting a clinically
relevant soil and application method that results in the most challenging test environment,
choosing at least two appropriate soil markers, selecting inoculation test sites, and
designating samples as positive and negative controls in the test design [4]. Additionally,
analytical methods for detecting residual bioburden require validation [1]. This research
upholds these guidelines in the testing of a reprocessing protocol under worst-case use
conditions.
Reprocessing of Single-Use Devices
There are several reprocessing guidance and regulatory documents related to
reprocessing validation, some of which pertain specifically to reusable devices (as
mentioned above) [1, 4] while others pertain specifically to single-use (disposable)
devices (SUDs). The FDA defines SUDS as a device “intended for one use, or on a single
patient during a single procedure” [2]. In some healthcare settings SUDs are reused
beyond their intended life in order to deliver patient care [9, 12, 13]. Regulated
reprocessing of SUDs is often performed by third-party reprocessors who are
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independent from healthcare facilities [21-23], although this is not always the case,
especially for low- and middle-income countries (LMIC) where in-hospital reprocessing
of SUDs is prevalent [9, 12, 13, 15, 20]. In these low-resource settings, medical devices
are often reprocessed at the user-facility level and not by third-party reprocessors [18,
19]. Despite the lack of regulation, it has generally been shown that the reprocessing of
SUDs is a safe practice if strict decontamination procedures are followed [16, 17]. In the
low-resource setting, the unequal distribution of medical technology and resources may
cause variations in reprocessing practices between hospitals on different levels of the
same tiered healthcare system [9, 13]. Due to the variation in practices, it is critical to
understand the types of devices being reprocessed. This body of research addresses this
need through a systematic investigation of the reprocessing practices for LMIC hospitals.

1.3 PURPOSE OF RESEARCH
The broad objective of this thesis is to validate a reprocessing protocol for SUDs
commonly reused in LMIC. In these studies, the bag-valve-mask (BVM) was chosen as
the primary SUD of interest. This objective will be accomplished by fulfilling four aims
as described in the individual chapters as follows:
Chapter 2: Document reprocessing practices in a tiered healthcare system. This will be
accomplished through the assessment of current SUD reuse practices in urban and rural
hospitals in Tanzania, in efforts to identify commonly reused SUDs and evaluate current
reprocessing procedures.

5

Chapter 3: Develop quantitative cleaning validation methods for reprocessing. This will
be accomplished by 1) completing a comprehensive design review and identifying
challenges to reprocessing BVMs; and 2) investigating three different residual bioburden
analysis methods for assessing the efficacy of decontaminating a disposable BVM.
Chapter 4: Evaluate reprocessing protocols in simulated worst-case scenarios. This will
be accomplished by investigating: 1) the impact of organic load and post-contamination
drying time on reprocessing protocol efficacy and 2) the effects of repeated use and
reprocessing on BVM functional performance.
Chapter 5: Define human factors affecting BVM reprocessing. This will be accomplished
by 1) creating a task analysis for BVM reprocessing, 2) defining key study output
variables, and by 3) establishing a usability study procedure that assesses defined study
outputs.
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CHAPTER TWO
MEDICAL DEVICE REUSE PRACTICES IN RURAL AND URBAN HOSPITALS IN
A LOW-RESOURCE SETTING
2.1 INTRODUCTION
The World Health Organization, supported by clinical studies, recognizes that
single-use medical devices (SUDs) are commonly reprocessed and reused beyond their
intended life in order to deliver patient care [1-10]. Termed medical device
“reprocessing”, such practices involve cleaning, disinfection or sterilization, and testing
before making SUDs available for reuse in hospitals. In general, reprocessing in low- and
middle-income countries (LMIC) is commonly performed at the user-facility level in a
hospital setting, in contrast to regulated third-party reprocessors frequently used in highincome countries [11-14]. Moreover, given the inequitable distribution of medical
technology resources in LMIC, variations in reprocessing practices across tiered
healthcare systems (e.g. national versus district hospitals) may exist within the same
country [8, 14, 15]. Given this variability of reprocessing practices, it is essential to
document the types of SUDs being reused and related reprocessing procedures utilized
within a given hospital system.
In general, studies have shown that reprocessing and reuse of SUDs within LMIC
hospitals can be safe as long as stringent standard operating procedures (SOPs) are
followed, which helps to reduce risks associated with inadequate cleaning and device
failure [2, 8, 20]. These SOPs must include device-specific cleaning and sterilization
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instructions, post-reprocessing inspection criteria and define a way to manage the number
of device reuses. The purpose of this investigation was to assess current SUD reuse
practices in urban and rural hospitals in Tanzania in efforts to identify commonly reused
SUDs and evaluate current reprocessing procedures.

2.2 MATERIALS AND METHODS
Tanzania is classified as a low-income country (<$1005 gross national income per
capita) with low (~3%) government expenditure on healthcare [21, 22]. Medical device
reprocessing methods were investigated within two urban hospitals (Urban1, Urban2) and
one rural (Rural1) hospital. Both of the urban hospitals are located in Dar es Salaam,
Tanzania’s largest and most populated city. The Urban1 hospital (1500 bed capacity
serving 1000-1200 inpatients weekly) is categorized as a national hospital in Tanzania’s
tiered healthcare system. The Urban2 hospital is categorized as a specialized hospital
(103 bed capacity). The Rural1 hospital is considered a regional referral hospital (420 bed
capacity serving approximately 2 million), located 300 km from the closest city of
Arusha—the only high standard hospital in the rural Manyara region.
On-site interviews with hospital personnel in the urban and rural hospitals were
conducted over a 14-day period in June 2017. Hospital personnel were selected for
interviews based on the following criteria: employed as a doctor, nurse, biomedical
technician, or biomedical engineer; available during the on-site visits; willing and
approved by supervisor to participate in the interview; and possessing direct knowledge
of reprocessing procedures within their hospital. Each participant was interviewed by a
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lead research team member using a structured questionnaire addressing the following
topics:
1) Are SUDs repeatedly reused in the hospital?
2) What are the common types of SUDs currently being reused?
3) What cleaning, decontamination, or other reprocessing procedures are used with the
SUDs?
4) Are inspection criteria or other validation protocols applied to the SUDs prior to reuse?

2.3 RESULTS
Urban Hospital Assessment
Hospital personnel interviews identified SUDs commonly reused within the urban
hospitals, including oxygen concentrator humidifier cups (Figure 2.1), oxygen tubes, bagvalve-masks, electrosurgical pencils (Figure 2.2), and electrosurgical dispersive
electrodes (Table 2.1). A written decontamination SOP for devices without electrical
components was identified, which involved exposure to a diluted bleach solution,
followed by a water rinse and air drying (Appendix C.1). The humidifier cups were not
considered to be at high risk for contamination and were rinsed using tap water before
reattachment to the oxygen concentrator (Figure 2.2). SUDs with electrical components
were wiped with an alcohol wipe and did not undergo additional reprocessing. No
inspection criteria were documented or in place for SUDs in either Urban1 or Urban2.
Hospital personnel conveyed that the SUDs underwent reprocessing and reuse until the
device malfunctioned. Therefore, the decision tree for reusing SUDs in the urban
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hospitals involved two key decision points: observed device malfunction during prior use
and identification of any SUD electrical components (Figure 2.3).

B

A

C

Figure 2.1. Identified Reused SUDs. Left: Oxygen concentrator and humidifier
attachment (non-functional). Right: (A) Electrosurgical pencil, (B) connector, (C)
Electrosurgical pencil and connector.

Table 2.1. Urban Hospital Reuse Practices. This provides a summary of reused SUDs
in Urban1 and Urban2 hospitals, availability of decontamination SOP, and application of
inspection criteria prior to reuse.
Single-Use Device

Reused?

SOP?

Humidifier Cup

√

√

Oxygen Tubes

√

√

Bag-Valve-Mask

√

√

Electrosurgical Dispersive
Electrode

√

Electrosurgical Pencil

√
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Inspection
Criteria?

Figure 2.2. Urban Hospital Humidifier Attachment Reuse. This reuse cycle pertains
to the oxygen concentrator humidifier cup attachments when not following the urban
hospital decontamination SOP.

Figure 2.3. Urban Hospital SUD Reuse. This reuse cycle is relevant to Urban1 and
Urban2.
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Rural Hospital Assessment
Hospital personnel interviews identified several commonly reused SUDs in the
rural hospital, including oxygen concentrator humidifier cups and disposable surgical
gowns (Table 2.2). Additionally, it was reported that electrosurgical pencils and
dispersal electrodes were not reused due to lack of device availability and lack of
confidence in the hospital staff’s ability to clean the device. Rural1 did not have a written
decontamination SOP for SUDs; instead, SUDs were cleaned in a detergent solution
without additional cleaning or sterilization procedures. Similar to practices in the urban
hospitals, humidifier cups were rinsed with water before reuse. Rural1 did not document
formal inspection criteria; SUDs were disposed if there were visible defects or if cleaning
was impeded but were otherwise reprocessed and reused until the device malfunctioned.
Aside from looking for obvious physical defects, the decision tree for reusing SUDs in
Rural1 involved one key decision point: identification of any electrical components for
the SUD (Figure 2.4).
Table 2.2. Rural Hospital Reuse Practices. This provides a summary of reused SUDs in
Rural1 hospital, availability of decontamination SOP, and application of inspection
criteria prior to reuse.
Single-Use Device

Reused?

Humidifier Cup

√

Surgical Gown

√

Electrosurgical
Dispersive Electrode
Electrosurgical Pencil
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SOP?

Inspection
Criteria?

Figure 2.4. Rural Hospital SUD Reuse. Current SUD reuse practices within a rural
Tanzanian hospital (Rural1).

2.4 DISCUSSION
This study identifies key risks in reprocessing procedures and provides useful
information to aid quality improvement in SUD reprocessing. The information provided
through the on-site interviews highlights key findings related to selection of cleaning
solutions for reprocessing and sorting devices based on both risks of infection and device
malfunction. In many cases, SUDs were continually reused until malfunctions occurred.
In all interviewed hospitals, there was an absence of documented and verified standard
operating procedures for cleaning, disinfection, and inspection, which are key aspects of
regulated reprocessing. There was widespread use of bleach due to having the following
properties: low cost, quick-acting microbicidal activity, and the ability to target a broad
spectrum of microorganisms. However, it was recognized that bleach would not be
compatible with devices containing electrical components, which led to the use of alcohol
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wipes as the primary disinfectant for such devices. Alcohol wipes can provide rapid
viricidal and bactericidal activity when used at appropriate concentrations (e.g. 60-80%)
but notably lack sporicidal action and the ability to penetrate surface-adhered bioburden
necessary for sterilizing medical devices [24]. It was noted that hospital personnel
expressed lack of confidence in cleaning effectiveness for some devices, which could be
addressed through well-designed validation studies. Additionally, validating devicespecific SOPs for reused SUDs and defining the number of safe reuse cycles, which is
recommended by international regulatory standards and medical professionals, can help
ensure safe reuse of these devices [12-17, 23, 24, 27].

2.5 CONCLUSION
This investigation revealed a clear need to document reprocessing methods and
SUDs commonly reused in LMIC hospitals. A broad range of reprocessed SUDs were
identified in the included Tanzanian hospitals. Both urban and rural hospitals identified
similar types of SUDs for reuse (Tables 2.1-2.2) but, reported varied reprocessing
procedures. This systematic documentation of unregulated reprocessing practices (Table
2.3) is a first step towards determining policies for safely reusing medical devices in
hospitals throughout Tanzania and training biomedical technicians/engineers to provide
support for such practices. While these hospital interviews provided valuable insight into
reprocessing practices and the reuse of SUDs, it remains to be determined if the SUDs
and reprocessing practices documented in this study are common across the broader
hospital system in Tanzania. Collaboration with academic institutions in the country is
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key to in-depth and formal documentation of reuse practices between hospital tiers within
Tanzania. Moving forward, next steps include formally documenting reuse practices at
different Tanzanian hospitals through collaboration with Tanzanian universities.
Additionally, ongoing efforts include the validation of identified reprocessing protocols
under realistic, worst-case conditions through microbiological testing and human factors
studies.

Table 2.3. Tanzanian Hospital Reuse Practices Summary. This provides a comparison
of reuse-practices between urban and rural hospitals in Tanzania.
Single-Use
Device

Hospital

Reused?

SOP?

No Electrical
Components

Urban

√

√

Rural

√

Has Electrical
Components

Urban

√

Rural
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Inspection
Criteria?
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CHAPTER THREE
REPROCESSING PROTOCOL EFFICACY AND RESIDUAL BIOBURDEN
ANALYSES
3.1 INTRODUCTION
Regulatory agencies define a single-use device (SUD) as a medical device that is
designated by the manufacturer for use during a single medical procedure on a single
patient and is intended to be discarded after the procedure [1-4]. However, used SUDs are
not discarded in all circumstances; rather, they are sometimes reprocessed for reuse using
specific methods for cleaning and disinfection. Recent trends indicate that regulated
reprocessing is often performed by third-party reprocessors who are independent from
healthcare facilities [4-8]. However, in-hospital reprocessing has been reported for many
different types of SUDs and remains prevalent in many low- and middle-income
countries (LMIC) [9-13].
The current investigation was motivated by a recent survey of in-hospital
reprocessing in Tanzanian hospitals that identified bag-valve masks (BVM) as a
commonly reused SUD [10]. BVM are medical devices commonly used in intensive care
units and other key hospital departments to treat patients requiring ventilation during
manual resuscitation [14, 15]. BVM are considered an essential piece of equipment for
newborn resuscitation [16-18]. Failure to establish breathing accounts for 19% of
neonatal deaths, while only 3% - 6% of babies born require basic resuscitation using a
BVM [19-21]. In LMIC with a high burden of neonatal mortality, inadequate supplies
and poorly functioning BVM can contribute to inconsistent resuscitation practices [16].
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Therefore, well-executed in-hospital reprocessing could support neonatal resuscitation
strategies by helping to maintain adequate supplies of BVM.
Recognized challenges with in-hospital reprocessing include variations in
reprocessing practices between hospitals and a need for device-specific protocols
defining reprocessing procedures and inspection criteria [8, 10, 12, 13, 22, 23]. In the
Tanzanian survey [10], hospital personnel reported that BVM were reprocessed using a
generalized decontamination protocol consisting of extended exposure to a dilute bleach
solution followed by a water rinse and air-drying (Appendix C.1). However, varied
reprocessing methods applied to some SUDs were noted, including use of alcohol wipes
and simple water rinsing when devices were perceived as low-risk of contamination [10].
At present, there are limited data available for reprocessing disposable BVM.
Manufacturers of reusable BVM propose some methods for decontamination in their
instructions for use, but validation data are not provided [24, 25]. Those methods
recommend the use of detergents and manual scrubbing for cleaning, the use of
glutaraldehyde or sodium hypochlorite solutions for chemical disinfection, and the use of
ethylene oxide or steam autoclaving for sterilization.
The purposes of the current study were: 1) to complete a comprehensive design
review and identify challenges to reprocessing BVMs; and 2) to investigate three
different residual bioburden analysis methods for assessing the efficacy of
decontaminating a disposable BVM.

3.2 MATERIALS AND METHODS
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Design Review
BVM designs have basic common features, including a soft polymer mask to
conform to the patient’s face, a deformable ventilation bag, a non-rebreathing valve
connecting the mask to one end of the bag, and an air intake valve at the opposite end of
the bag. Worldwide, self-inflating BVM are the most common manual ventilation device
used in neonatal and adult intensive care units [15, 18, 26]. As described by Davies, et al.
[15], self-inflating BVM are portable and versatile due to their ability to fill with ambient
room air or with gas supplied from an external oxygen tank. When the ventilation bag on
a self-inflating BVM is compressed, the non-rebreathing valve directs gas from the bag to
the patient. As pressure on the bag is released, the non-rebreathing valve closes, and gas
exhaled by the patient is directed out of the mask through a separate channel in the nonrebreathing valve while the bag automatically re-inflates through the air intake valve.
BVM can either be reusable or disposable. For the purposes of the current study,
disposable BVM, hereafter referred to as Test BVM (Figure 3.1), were purchased from a
commercial source (Model Life-100, Life Corporation, Milwaukee, WI). According to
specifications provided by the manufacturer, the Test BVM consisted of a clear face
mask fabricated from a thermoplastic polymer (polyvinyl chloride) with a removable
rigid plastic one-way valve housing a hydrophobic filter (Filtrete™, 3M Corporation, St.
Paul, MN). This mask features a 15-mm diameter air intake opening and a hydrophobic
filter above the valve to protect BVM components from body fluids.
Several design features of the Test BVM were considered reprocessing
challenges, including small crevices near the valve attachment, contours on the outside
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surface, and tight folds inside the mask (Figure 3.1). These features are opportunistic
areas for bacteria, microbes, and physical debris buildup. The mask is made of a pliable
material, which can add to the challenge of reprocessing [27]. Considering regulatory
demands for worst-case contamination conditions [1], the entire inside of the mask,
including the tight folds and crevices were identified as probable worst-case locations
where organic material would likely be present and could become entrapped. For this
reason, residual bioburden measurements were sampled from the entire inside of the
mask, including the tight folds and crevices. For testing, a total of five Test BVM were
purchased. Each mask was cut into two equal halves (Figure 3.1), thus producing two
samples for analysis. The total inside surface area of each mask half was measured from a
digital laser scan and measured 93.04 cm2. Each of the five decontamination protocols
were repeated on two mask halves (n=2).

Figure 3.1. Test BVM Mask. This device consisted of a pliable facemask and a rigid
non-rebreathing valve. All residual bioburden analysis methods were completed on
masks that were cut in half after removal of the valve.
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Sample Preparation and Contaminants
The BVM is considered an oronasal mask typically covering a patient’s mouth
and nose [28] and consequently, it may contact saliva, mucus, and microbial flora found
in the upper respiratory tract. Many different bacteria can colonize the upper respiratory
tract. Staphylococcus epidermidis is among the most common bacterial species to be
found in the nasal and paranasal sinuses [29]. This gram-positive bacterial species was
used in the current study to contaminate the Test BVM, as it is prevalent on human skin
and most surfaces and forms a biofilm. This makes S. epidermidis a likely microorganism
contaminating the BVM during use [30] and suitable for use in the current study.
Worst-case contamination conditions were achieved by fully submerging the Test
BVM mask halves into a soil solution consisting of standard mucus test soil simulating
mucus exposure from a cystic fibrosis patient [31] combined with Staphylococcus
epidermidis ATCC 12228 (American Type Culture Collection, Manassas, VA). A 2%
transfer of S. epidermidis ATCC 12228 stock culture to sterile Tryptic Soy Broth was
prepared (1:49 dilution of culture to media) to obtain a 100 mL solution (Appendix B.1).
The culture and media were then incubated overnight at 37˚C. The simulated mucus soil,
termed Artificial Mucus Soil (Appendix B.1), was prepared according to an international
standard for validation of cleaning methods for reusable medical devices [31]. The
components of the Artificial Mucus Soil (mucin from pig mucosa, casein hydrolysate,
sodium chloride, diethylene triaminepentaacetic acid, ASTM Water Type I, potassium
chloride, salmon sperm DNA, freeze dried egg yolk emulsion, and phosphate buffered
saline) were mixed on a stir plate at 20˚C - 25˚C to produce a uniform solution. This
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artificial soil provided protein, total organic carbon, nucleic acids, and carbohydrates as
cleaning markers for the residual analyses. The overnight S. epidermidis cultures were
added to Artificial Mucus Soil at a concentration of 10% inoculum, which provided the
addition of bacteria as a cleaning marker for the residual analysis. The Test BVM were
fully immersed in the Artificial Mucus Soil containing the S. epidermidis. This mixture
was incubated for 24 hours at 37˚C and, set out to dry for 15 minutes before undergoing
one of five reprocessing protocols. Inoculum concentrations for the decontamination
studies can be found in Appendix A.1.
Decontamination Protocols
Decontamination requires cleaning of the device to the point where visible
bioburden is removed. According to FDA regulatory classifications, BVM are semicritical reprocessed devices due to contact with mucous membranes (but not sterile
tissue); therefore, the decontamination protocols for cleaning must remove visible
bioburden and achieve high-level disinfection to eliminate microorganisms [1]. High
level disinfection intends to kill vegetative bacteria, but it does not eliminate all spores
[32]. High-level disinfection requires a 6-fold reduction of colony forming units (CFU),
plus overkill as a measure of microorganisms in residual bioburden. A high log reduction
value corresponds to an overall high bioburden removal as a result of cleaning and
disinfection. This 6-fold reduction in CFU was the targeted goal for the experimental
decontamination protocols in the current study.
Five decontamination protocols, including three experimental protocols and
positive and negative controls, were applied to the Test BVM masks following
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contamination. The negative control was designed to yield a high bioburden and included
masks that did not undergo any decontamination (Figure 3.2). The positive control was
designed to eliminate all bioburden. The positive control consisted of submerging the
BVM in full strength (5.25%) sodium hypochlorite solution (Clorox bleach, The Clorox
Company, Oakland, CA), then hot (>40˚C) water with non-enzymatic detergent (VersaCleanTM Multi-Purpose Cleaner, Thermo Fisher Scientific, Waltham, MA), and lastly in
filtered deionized water (ASTM type I) (Figure 3.3). For each protocol step, the mask
was sealed in a container with the appropriate decontamination agents for that step and
placed on a vortex mixer for one minute. Following this, the same mask and container
were sonicated for 10 minutes before moving to the next decontamination agent.
The three experimental decontamination protocols were chosen based on hospital
reprocessing observations at three hospitals in Tanzania [10]. The Alcohol Wipe protocol
involved wiping the entire in-side of the mask with one 70% isopropyl alcohol wipe
(Medium Sterile Alcohol Prep Pads (2.7 × 6.6 cm), Fisher HealthCare, China) (Figure
3.4). The Water Rinse protocol involved submerging the entire mask half in ASTM Type
I water for 10 minutes (Figure 3.5). The Soap and Bleach protocol involved sequential
10-minute submersion of the mask half in a 0.5% sodium hypochlorite solution, a nonenzymatic detergent (1:10 dish soap to water), and ASTM Type I water (Figure 3.6).
Following decontamination, each mask was air-dried for 10 minutes before being
evaluated for residual bioburden.
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Figure 3.2. Negative Control Protocol.

Figure 3.3. Positive Control Protocol.

Figure 3.4. Alcohol Wipe Protocol.

Figure 3.5. Water Rinse Protocol.

Figure 3.6. General Disinfection Protocol (soap and bleach). This soap and bleach
protocol is currently in use at an urban Tanzanian hospital [10].
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Residual Bioburden Analytical Methods
Three analytical methods were selected to evaluate the residual bioburden on the
Test BVM following each decontamination protocol (Table 3.1). Sample collection for
Metrics 1 and 3 involved swabbing the total inside surface area of each half BVM
immediately after cleaning, except for the negative control cases that were swabbed 24
hours after contamination. Sample collection for Metric 2 involved swabbing
approximately one-fourth of the inside surface area due to the manufacturer’s
recommendation to use a small sampling area.
Table 3.1. Residual Bioburden Analyses.

Metric

Metric 1

1

Residual
Bioburden
Method

Tests For

Units

Target

ChannelCheck™

Protein,
Carbohydrates,
Hemoglobin

N/A

No Color
Change

Presence of ATP

RLU

< 100

Removal of Bacteria

Log
Reduction of
Bacteria

≥ 6-log
reduction

2

1
2

Metric 2

Ruhof ATP
Complete®

Metric 3

Standard Plate
Count

Healthmark Industries Company, Inc, Fraser, MI
Ruhof Corporation, Mineola, NY.
Metric 1 was a commercial method that provided a quick (~2 minutes), qualitative

assessment of cleanliness by detecting the presence of residual carbohydrates, protein,
and hemoglobin on sample swabs. Test strips provided by the manufacturer featured
three colored pads that indicated the presence of physical bioburden in the swabbed
region. According to the manufacturer, the detection limits for the test strips are ≥210
µg/mL for carbohydrate, ≥120 µg/mL for protein, and ≥0.25 µg/mL for hemoglobin. For
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this study, decontamination targets were met, when both trials showed no indicator color
change on any test strip pad. This was consistent with reduction of residual
carbohydrates, protein, and hemoglobin below detection limits during decontamination.
Metric 2 (Appendix B.3) was a commercial method that provided a quick (~10
seconds), quantitative assessment of cleanliness by detecting the presence of residual
ATP on sample swabs. Reagent vials provided by the manufacturer emit
bioluminescence, which correlates to certain ATP levels and was detectable as light
emission when inserted into a handheld device also provided by the manufacturer.
According to the manufacturer, the detection limit is 0.2 mg protein per swab, and a
surface can be considered “clean” if the RLU (relative luminescence units) value
displayed is less than 100. For this study, decontamination targets were met when both
trials had RLU less than 100.
Metric 3 (Appendix B.2) was a commonly utilized microbiological technique
(standard plate count) that provided a quantitative assessment of disinfection by detecting
the presence of residual bacteria on sample swabs, which present as CFUs on agar plates.
Plate counts of CFUs were repeated in triplicate for swabs from each Test BVM half
mask, averaged, and then divided by the plate dilution to obtain the concentration of
bacteria in the original sample. Overall log reduction of CFUs for a given
decontamination protocol was calculated as the difference in bacterial concentration
following the decontamination protocol (CP) relative to the negative control sample (CNC)
(Equation (2.1)).
log reduction in bacteria = log(𝐶𝑁𝐶 ) − log(𝐶𝑃 ) (Equation 2.1)
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Sample collection involved swabbing the designated inside surface area of each
half mask. Following instructions for use for Metric 1, swabs were placed into sterile test
tubes with 10 mL of sterile Millipore (ASTM Type I) water and vortexed for one minute,
followed by full immersion of the provided test strips into the solution and manual
agitation for 10 seconds. The test strips were removed and held horizontally for 90
seconds prior to reading results. The test strips were compared to the color chart provided
by the manufacturer, and the presence or absence of residue was recorded. Following
instructions for use for Metric 2, swabs were placed in provided reagent vials and gently
shaken for 3 seconds prior to inserting individual vials into the hand-held unit by the
manufacturer and recording the displayed RLU value. Following standard
microbiological methods for Metric 3, swabs were placed into sterile test tubes with 10
mL of sterile Millipore (ASTM Type I) water and vortexed for one minute. A ten-fold
dilution series was prepared, plated onto agar (Tryptic Soy Agar, Remel, Lenexa, KS),
and incubated for 24 hours at 37˚C. Results were determined by manually counting CFUs
for each plate.

3.3 RESULTS
Design Review and Impact on Decontamination
Careful review of the Test BVM identified several design features that were
considered reprocessing challenges (Figure 3.1). The mask included contours on the
outside surface, flaps of pliable materials, tight folds, and rounded cavities on the interior
surface. These mask features could become exposed to mucous and other biological
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contaminants from the patient while wearing the mask, or during handling. The nonrebreathing valve had a complex geometry, with crevices and other small design features,
dead-end chambers, and an in-line filter. If the valve remained assembled with the mask,
the valve-mask interface would present an additional challenge in the form of a
circumferential small crevice between the two parts. Upon disassembly from the mask,
the tight fit of the modular connection may be difficult to reassemble and could be a site
for potential failure after multiple reprocessing trials.
As anticipated from the design review, the BVM mask design features negatively
impacted the performance of the decontamination protocols. Based on visual examination
of the half masks, tight folds and rounded cavities on the interior surface of the mask
retained more water and bioburden than other areas of the mask. This was most prevalent
after the mask was removed from the soil solution and allowed to dry, when noted mask
regions contained pools of the soil solution. Such areas were more difficult to reach
during manual cleaning with the alcohol wipes compared to protocols based on mask
submersion in cleaning solutions. This was reflected in the inconsistent results for the
Alcohol Wipe protocol (Figure 3.4) using Metric 1 and the large inter-trial differences in
the quantitative cleanliness values for Metric 2 and Metric 3 during the Alcohol Wipe
protocol (Tables 3.2-3.4). For example, the Alcohol Wipe protocol reached 8log10 CFU
reduction for trial 1, consistent with a high-level disinfection benchmark, but only
reached 3log10 CFU reduction for trial 2. One possible reason for the inconsistency was
inadequate wiping of the inner folds of the BVM mask during the second trial.

33

Table 3.2. Metric 1 Results.
Protocol

Metric 1
Trial 1
Protein Carb1

Negative
Control
Water
Rinse
Alcohol
Wipe
Soap and
Bleach
Positive
Control
1
Carbohydrates
2
Hemoglobin

Trial 2
Protein Carb1

Hb2

Target met?
Hb2

Yes

Yes

No

Yes

Yes

No

No

No

Yes

No

Yes

Yes

No

No

No

No

No

No

Yes

No

No

No

No

No

Yes

Yes

No

No

No

No

No

No

No

No

Yes

Table 3.3. Metric 2 Results.
Protocol
Trial 1
9999
9999
2343
0
0

Negative Control
Water Rinse
Alcohol Wipe
Soap and Bleach
Positive Control

Metric 2
ATP Value (RLU)
Trial 2
3967
7112
8948
6
0

Target met?
No
No
No
Yes
Yes

Table 3.4. Metric 3 results.
Protocol
Negative Control
Water Rinse
Alcohol Wipe
Soap and Bleach
Positive Control

Metric 2
Log Reduction in Bacteria
Trial 1
Trial 2
0
0
3.7
2.5
8.3
3.3
8.3
7.2
8.3
7.2
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Target met?
No
No
No
Yes
Yes

Residual Bioburden Analysis
All three methods for assessing residual bioburden required training of personnel
based on instructions for use (Metrics 1 and Metrics 2) or standard microbiological
techniques (Metric 3). Metric 1 required little training outside of the swabbing technique.
However, Metric 1 was a qualitative assessment judged by the user performing the test
and results were highly subjective due to differences in individual ability to identify a
change in color. Metric 2 required ample training time for: 1) proper swabbing technique;
2) preparing the swab and reagent vial for insertion into the handheld device; and 3)
operating the device. Metric 3 required time-intensive training for: 1) cell culturing
techniques and use of lab equipment; 2) growing stock inoculum and culturing of
bacteria; 3) proper inoculation of the BVM masks; and 4) growing bacterial samples on
agar plates.
Based on these preliminary data, the Alcohol Wipe and Water Rinse protocols
(Figure 3.4 and Figure 3.5, respectively) were ineffective or inconsistent at meeting
decontamination targets. Overall, only the positive control protocol (Figure 3.3) met the
decontamination targets for Metric 1 (Table 2.1) and only the Soap and Bleach (Figure
3.6) and positive control protocols met the decontamination targets for Metric 2 and
Metric 3 (Table 3.3 and Table 3.4). Full standard plate count data can be found in
Appendices A.2 and A.3. The qualitative analysis used for Metric 1 had inter-trial
variation, with indicators meeting cleanliness benchmarks (no color change) in trial 1 but
not trial 2 for both the Alcohol Wipe and Soap and Bleach protocols. A color change was
noticed for the hemoglobin indicator in the positive control protocol, but this was
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considered a false positive because of bleach present. The quantitative analysis used for
Metric 2 and Metric 3 had large inter-trial differences for the Alcohol Wipe protocol, as
mentioned above, but little inter-trial variations for the other protocols. For example, the
RLU values for Metric 2 varied within the 0 - 100 RLU benchmark (e.g. 6 RLUs in Trial
2 for the Soap and Bleach protocol), but this is consistent with the sensitivity range of the
system.
All three methods for assessing residual bioburden required some use of
consumable materials and/or durable equipment. Metric 1 required use of consumable
materials (swabs, test strips) to provide a qualitative assessment of residual bioburden
(proteins, carbohydrates, hemoglobin) based on color change. Metric 2 required use of
consumable materials (swabs, reagent vials) and durable equipment (refrigerator for
reagent vials, hand-held device for measuring the RLU of emitted bioluminescence) to
provide a quantitative assessment of residual ATP. Metric 3 required use of consumable
materials (swabs, bacteria and growth media, agar plates, cell spreaders, pipette tips) and
durable equipment (incubator, pipettes, biological hood) for measuring bacterial CFUs to
provide a quantitative assessment of residual bacterial concentration.

3.4 DISCUSSION
This study completed a comprehensive design review of a disposable BVM to
identify potential challenges to reprocessing and investigated three different methods for
assessing residual bioburden on the BVM masks following decontamination. Overall,
only the positive control protocol (Figure 3.3) met the decontamination targets for Metric
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1 and only the Soap and Bleach (Figure 3.6) and positive control protocols met the
decontamination targets for Metric 2 and Metric 3. The Alcohol Wipe and Water Rinse
protocols (Figure 3.4 and Figure 3.5, respectively) were ineffective or inconsistent at
meeting decontamination targets (Tables 3.2-3.4). These findings provide a first step
toward development of device-specific protocols that define uniform reprocessing
procedures and inspection criteria for hospitals choosing to reprocess BVM. Based on a
small sample size, these preliminary results support the use of bleach-based
decontamination protocols that submerge disposable BVMs into cleaning and
disinfection solutions rather than wiping.
The BVM mask geometry negatively impacted the performance of the
decontamination protocols. Flaps of pliable materials, tight folds and rounded cavities on
the interior surface of the mask were challenging to clean and contributed to large
variations in cleanliness for Metric 2 and Metric 3 in the Alcohol Wipe protocol.
Although only the BVM mask was evaluated in the decontamination protocols, the
design review identified additional challenges associated with the modular connection of
the non-rebreathing valve, as well as the complex valve geometry having small crevices,
dead-end chambers, and a filter. All three methods required some level of training based
on instructions for use (Metric 1 and Metric 2) or standard microbiological techniques
(Metric 3). Metric 1 seemingly required the least training but generated the least
consistent results. The time required for assessment after sample collection ranged from
approximately 1-3 minutes for Metric 1 and Metric 2 and approximately one day for
Metric 3.
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Several drawbacks were noted for each of the residual bioburden assessment
methods. Metric 1 required subjective interpretation of color change and was
incompatible with protocols involving bleach, which induced a color change falsely
indicating the presence of hemoglobin. This inaccuracy would be problematic if
hemoglobin was a routine contaminant for a given SUD. Possibilities for overcoming
color interpretation include use of a colorimeter to compare the test strip to the color
standard or taking pictures of the test strips in a uniform, well-lit environment and
completing hue analysis. Drawbacks for Method 2 and Method 3 center on the need for
consumables and durable equipment and extended training time, as mentioned in the
results.
Several study limitations are noted. These results may not be generalizable, as
only one model of disposable BVM was evaluated in this study. This underscores the
need for device-specific validation of reprocessing protocols, as design features vary
between BVM and can impact the effectiveness of decontamination protocols. While the
design review involved the entire Test BVM (full mask and non-rebreathing valve), the
analytical methods for residual bioburden analysis (Metrics 1-3) were evaluated using
mask halves (n=2). This approach provided for efficient screening of the analytical
methods, but it is recognized that additional evaluation of the full BVM (mask and valve)
and statistical comparisons are needed for definitive conclusions related to the
decontamination protocols. Finally, all analyses were performed by a team of five trained
bioengineering graduate students with faculty supervision, which does not represent the
personnel likely to conduct decontamination of disposable BVM in a healthcare setting.
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3.5 CONCLUSION
This study describes an initial experimental approach for validating BVM
decontamination protocols and generating data for objective assessment of reprocessing
and reuse practices. The data support positive decontamination outcomes using the
bleach-based in-hospital reprocessing protocol currently in use in some Tanzanian
hospitals [10]. However, design features of the Test BVM mask presented clear
challenges to cleaning and drying during the different decontamination protocols. Based
on these preliminary results, continued assessment of the Soap and Bleach
decontamination protocol (Figure 3.6) using complete dis- posable BVMs (full mask and
the non-rebreathing valve connected to the mask) exposed to simulated use is warranted.
Detailed inspection criteria, factors related to mask/valve assembly and disassembly, and
the maximum number of intended reprocessing cycles, remain to be determined. Given
proper consideration of training time and available resources, well-executed in-hospital
reprocessing could support neonatal resuscitation strategies and other demands for
manual resuscitation by helping to maintain adequate supplies of BVM.
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CHAPTER FOUR
REPROCESSING VALIDATION FOR THE BAG-VALVE-MASK IN SIMULATED
WORST-CASE USE CONDITIONS
4.1 INTRODUCTION
Single-use medical devices such as the disposable bag-valve-mask (BVM)
are commonly reprocessed in hospitals in low- and middle-income countries due to
resource constraints [1-3]. BVM are a critical medical device for neonatal resuscitation
and the prevention of neonatal mortality associated with lack of breathing, which has a
prevalence of roughly 19% in low- and middle-income countries [4-6]. Establishing
rigorous reprocessing procedures for this device can enable safe reuse in low-resource
healthcare settings.
In a recent study evaluating different methods for quantifying decontamination of
a disposable BVM , a simple sodium hypochlorite and detergent solution was proven
effective for reducing bioburden and bacterial contamination under optimal cleaning
conditions, but various BVM design features negatively impacted decontamination
efficacy for some protocols [8]. However, only the soil application method could be
considered a possible worst-case scenario in that study. The current study expands on
simulated worst-case use and reprocessing scenarios.
Sodium hypochlorite provides for high-level disinfection when appropriate
concentrations (0.5%, 5,000 ppm chlorine) and contact time are implemented in a general
disinfection protocol (referred to as ‘Reprocessing Protocol’ in this paper). Despite its
lack of compatibility with some materials, this chemical is an optimal disinfectant in the
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healthcare setting due to its quick-acting bactericidal activity, ability to deactivate a wide
range of microbes, high water solubility, and affordability [9]. Hypochlorous acid
provides the primary microbicidal activity of sodium hypochlorite through mechanisms
likely related to disruption of the cell membrane and DNA synthesis [10, 11]. When
considering factors contributing to worst-case disinfection with sodium hypochlorite, it is
critical to consider changes in pH, chlorine concentration, and disinfectant contact time
during reprocessing. Hypochlorous acid concentration heavily depends on the pH of the
solution: as pH of the diluted solution increases, the microbicidal activity through the
hypochlorous acid decreases exponentially [11]. Optimal microbicidal activity for this
diluted solution can be found at a pH of approximately 6 [9]. Since diluted sodium
hypochlorite solutions have a high pH, there are higher concentrations of the OCl- ion.
This means that having the proper contact time to achieve disinfection is crucial [10, 11].
However, under less than ideal conditions, the sodium hypochlorite efficacy can become
compromised.
Several variables can impact the disinfectant quality, including the cleaning agent
and disinfectant properties, presence of contaminants, UV exposure, and water quality [9,
10, 12-14]. Accumulation of organic matter (biofilms and other bioburden) through
repeated reprocessing cycles negatively impacts the microbicidal performance of sodium
hypochlorite disinfection solution, [9, 34, 35]. Additionally, prompt cleaning of used
devices is important to avoid drying of attached bioburden [15-17]. Prion tissue
adsorption on stainless steel [30, 32, 33, 42] and challenges removing dried bioburden
with a water flush through endoscope channels [31] have proven problematic. These
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studies have shown negative effects of prolonged post-contamination drying time (i.e. the
time between device use and the initiation of its cleaning or disinfection) on reprocessing
protocol efficacy, making it a variable of interest in the current study.
The objective of this study was to validate the reprocessing of a disposable BVM
under simulated worst-case use conditions. This was accomplished by investigating i) the
impact of organic load and post-contamination drying time on reprocessing protocol
efficacy and ii) the effects of repeated use and reprocessing on BVM functional
performance. The impact of organic load and post-contamination drying time on
reprocessing protocol efficacy (Sections 4.3.1 and 4.3.2 respectively) were evaluated with
the two cleaning validation methods used previously [8]. The effects of repeated use and
reprocessing on BVM functional performance were measured by tidal volume, a key
ventilation parameter (Section 4.3.3).

4.2 METHODS AND MATERIALS
4.2.1. Simulated Worst Case Testing Overview
Experimental Design
This current study expanded on simulated worst-case conditions related to drying
time, accumulated organic load in disinfectant solutions, and damage accumulation
during repeated use/reprocessing. The impact of worst-case use conditions was studied in
two parts: simulated worst-case drying time (Section 4.2.2) and simulated worst-case use
conditions (Section 4.2.3). The objective of the first study was to examine the impact of
post-contamination drying time on reprocessing protocol (Figure 4.1) efficacy. The
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objective of the second study was to evaluate the effects of worst-case reprocessing
conditions (Figure 4.2), including prolonged post-contamination drying time, on the
ability of the bleach-based reprocessing protocol to meet disinfection targets. The
simulated worst-case use testing conditions (Section 4.2.3) are defined as follows: highly
diluted bleach pH (~11), high organic load (240 mL, equivalent to using a sodium
hypochlorite solution that has been used in the reprocessing of 80 masks), and prolonged
post-contamination drying time. A bleach pH of 11 was chosen to represent a worst-case
condition: extremely low hypochlorous acid presence. The organic load volume was
chosen to equate to >20% of the total volume of the soiled disinfectant solution, as a
volume of 10-20% organic load has been shown to significantly impair the chlorine
activity in other soiling studies [34, 35].
All testing in simulated worst-case conditions (Sections 4.2 and 4.3) utilized the
reprocessing protocol as mentioned in the introduction (Figure 4.1) and Artificial Mucus
Soil and Staphylococcus epidermidis (ATCC12228) as the contaminants. The bleachbased reprocessing protocol involved a 10-minute submersion of the device in a 0.5%
sodium hypochlorite solution, followed by a 10-minute submersion in non-enzymatic
detergent (1:10 dish soap to water), 1-minute submersion in ASTM Type I water, and 10minute air dry (Appendix C.1):
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hypochlorit
10 min

Soak in
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Submerge
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Air
dry
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Figure 4.1. Reprocessing Protocol. General bleach-based disinfection protocol utilized
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Figure 4.2. Experimental Design for Worst-Case Use Conditions.
Contaminants and Cleaning Validation Methods
Simulated worst-case soiling conditions utilized a mixture of
Staphylococcus epidermidis and Artificial Mucus Soil (referred to in this paper as ‘soil
mixture’) [18], which provided cleaning markers for the validation process, including
protein, total organic carbon, nucleic acids, and carbohydrates. S. epidermidis
ATCC12228 is gram-positive and commonly found in the human upper respiratory tract
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and paranasal sinuses as well as on skin, which made it a suitable inoculum species. The
bacteria were prepared as a 2% transfer of S. epidermidis stock culture in sterile tryptic
soy broth, producing a total volume of 100 mL (Appendix B.1). These cultures were then
incubated for 24 hours at 37°C and added in a 1:9 ratio to the Artificial Mucus Soil. This
mixture was then incubated for 24 hours at 37°C. The Artificial Mucus Soil (Appendix
B.1) was prepared according to an international standard (ASTM F3208) for the
validation of cleaning methods for reprocessed medical devices and contained the
following components: dried pig mucin, casein hydrolysate, sodium chloride, diethylene
triaminepentaacetic acid, ASTM type I water, potassium chloride, salmon sperm DNA,
freeze dried egg yolk emulsion, and phosphate buffered saline.
In both parts of the simulated worst-case testing, once samples reached their
designated drying time after exposure to the soil mixture, they were immediately tested
for adenosine triphosphate (ATP) presence and microbial growth or put through a
reprocessing protocol and checked for ATP presence and microbial growth (Appendix
B.3). The detection of ATP indicates that the surface tested can support microbial life.
This method has been demonstrated to be an effective indicator of cleaning and has a
detection limit of 0.2 mg protein per swab [19]. Sample collection swabs, provided by the
manufacturer, were inserted into a handheld device that measures bioluminescence.
According to the manufacturer, the sampled area is considered “clean” if the RLU
(relative luminescence units) value displayed is less than 100. For this study, a successful
reprocessing protocol will yield RLU values of less than 100 in all trials.
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The standard plate count (Appendix B.2), a widely used microbiological
technique for determining bacteria counts, provided the number of colony-forming units
(CFUs) and includes the following steps. Surface samples were taken from each PVC
sample, placed into 10 mL of sterile deionized water (ASTM Type I), and vortexed for
one minute. From this, a ten-fold serial dilution was performed, spread onto prepared
agar plates (Tryptic Soy Agar, Remel, Lenexa, KS), and incubated for 24 hours at 37°C.
CFUs were manually counted and recorded after the incubation period. Results are
recorded as the ‘log reduction of bacteria’ using Equation 4.1, where CClean is the log
value of CFUs eliminated from the sample (upon cleaning) and CDry is the log of the
starting number of CFUs prior to cleaning:
log reduction in bacteria = log(𝐶𝐷𝑟𝑦 ) − log(𝐶𝐶𝑙𝑒𝑎𝑛 )

(4.1)

The Spaulding Classification provides the appropriate disinfection targets for
reprocessed medical devices [20]. For a semi-critical reprocessed device such as the
BVM, a 6x reduction in bacteria achieved through high level disinfection (or
sterilization) is required.
BVM Units Tested
The following masks (Table 4.1) experienced different reprocessing conditions
and levels of physical damage, which were intended to represent the effects of repeated
use and reprocessing. Two BVM designs, which are referred to as ‘Mask 1 and Mask 2’,
were chosen due to their wide use in hospitals around the world. A third brand (Mask 3)
was made of the same material as Masks 1 and 2 and was used to provide sample
coupons for the drying time studies.
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Table 4.1. BVM Units Tested.
BVM
Unit

Images

Description

Mask
1A

Mask
1R

Mask
1PD

(1)

(2)

(3)

Mask
1FD

Comprised of a
cushioned PVC face
mask (1,2), one-way
silicone rubber valve,
and PVC selfinflating bag (3).
New models
used.USE, PERFORM
Same model as Mask
1 but underwent 20
reprocessing cycles
with 24 hours of
post-contamination
drying.PERFORM
Mask 1PD had a one
inch slit along the
bottom of cuff so
partial deflation
occurred. Mask 1FD
had a one inch slit on
side of cuff,
rendering it
deflated.PERFORM
Abraded with P40
grit sandpaperD until
significant visible
damage was
observed (no
puncturing).PERFORM

Mask
1A
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Comprised of a
cushioned PVC face
mask (1,2), one-way
liquid silicone rubber
valve, and SEBS
self-inflating bag (3).
New models
used.PERFORM

Mask
2B

(1)

(2)

(3)

Comprised of PVC,
featuring a rigid,
non-rebreathing
valve.DRY

Mask
3C

A

Laerdal® Adult Mask #4, Laerdal Medical AS, Wappingers Falls, NY
Ambu® SPUR® II, Ambu Inc., Columbia, MD
C
Model Life-100, Life Corporation, Milwaukee, WI
D
Shopsmith® 4.5 x 5.5 in L 40-Grit Commercial Sanding Sheets, RLF Brands, Dayton,
OH
DRY
Used in Simulated Worst-Case Drying Time testing
USE
Used in Simulated Worst-Case Use Conditions
PERFORM
Used in Bag-Valve-Mask Functional Performance
B

4.2.2. Simulated Worst-Case Drying Time
Sample Preparation
Eighteen sample coupons were prepared. Nine samples underwent drying
and subsequent cleaning with the reprocessing protocol (Figure 4.1). These samples are
referred to as ‘dried and reprocessed’. Six samples underwent drying only (referred to as
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‘dried only’), and 3 samples served as the negative control. The negative controls were
contaminated but did not undergo any drying or cleaning and were used as benchmarks
for comparison with the cleaned samples. Coupons from Mask 3 were cut into 8 cm2
samples and sonicated in full-strength 5.25% sodium hypochlorite (Clorox® bleach, The
Clorox Company, Oakland, CA) for 20 minutes. Following this, they were soaked in
filtered deionized water (ASTM Type I) for 10 minutes and allowed to dry in a sterile
environment for 10 minutes.
After the final incubation of the soil mixture as described in Section 4.2.1, 0.2 mL
of the bacteria and Artificial Mucus Soil were spread over 8 cm2 on each sample using a
plate spreader and dried for 0 hours, 4 hours, 8 hours, and 24 hours in ambient conditions
in a class II biosafety cabinet. These times and soil mixture volume were chosen based on
drying times used in relevant literature [31] and results from a preliminary drying time
study in which coupons were visually wet for up to 240 minutes and were visually dry
after 1440 minutes. In that preliminary study, sample coupons were inoculated with 0.4
mL of soil mixture over 8 cm2. Half of the sample coupons (4 cm2) were designated for
sampling—one half for ATP testing and one half for standard plate count.
4.2.3. Simulated Worst-Case Use Conditions
Sample Preparation and Contamination
Thirteen disposable units of Mask 1 were selected, three of which served as the
negative control (no cleaning or disinfection). These masks came in sealed bags, which
were opened in a sterile environment immediately before use. The same 1:9 mixture of
Staphylococcus epidermidis and Artificial Mucus Soil as described in Section 4.2.1 was
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prepared, producing a total volume of 2500 mL. After the soil mixture was incubated for
a final time (24 hours), each mask was submerged in the mixture for 5 minutes before
drying for 12 hours. Following the drying time, a total of 10 masks underwent the
reprocessing protocol (Figure 4.1). Five masks were reprocessed using a sodium
hypochlorite solution of pH >11 while the remaining five were subjected to a sodium
hypochlorite solution (pH >11) with 24% (vol/vol) of added organic matter (Artificial
Mucus Soil). The masks subjected to the sodium hypochlorite and organic matter are
referred to as the ‘With Organic Load’ and were not introduced to the disinfectant
solution until 10 minutes after the organic matter had been added to the sodium
hypochlorite. This was done to allow the pH to stabilize after organic load was added
(Appendix B.4). Half of the inside of each mask was designated as the sample collection
area (173 cm2 per half): one half for ATP testing and one half for the Standard Plate
Count.
4.2.4. Bag-Valve-Mask Use and Functional Performance
BVM Ventilation Parameters and Technique
The BVM provides positive pressure ventilation during manual resuscitation.
There are two key measures of ventilation performance, as established by the American
Heart Association and European Resuscitation Council: tidal volume and ventilation rate
[21, 22]. Tidal volume is measured in milliliters of air and corresponds to the amount of
air delivered to the patient airways as the BVM is squeezed. For the purposes of this
research, the ventilation rate and duration were kept constant, and the tidal volume was
provided by manikin simulation software. Successful ventilation is dependent upon
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proper patient positioning and assumes no physical obstructions are present in the
patient’s airways.
Repeated use and reprocessing have the potential to impair the BVM’s ability to
function as intended; this is an area that has largely been unexplored. The anticipated
effects of repeated reprocessing are related to key characteristics of ventilation. Proper
ventilation is accomplished first through tilting of the patient’s head and lifting of the
chin [23]. In the performance test setup, the manikin’s head was fully tilted back so that
the patient airway was open. Second, the mask must achieve an adequate seal. Use of the
two-handed E-C clamp in this study (Figure 2.3) was not only representative of common
clinical technique but also recommended due to the improved sealing of the mask it
provides [21, 24-26]. The last key consideration is the volume of air delivered, which is
influenced by squeeze rate, bag size, and hand positioning [27]. During BVM use, the
provider should be able to deliver a tidal volume of 400-700 mL of air with each squeeze,
deliver 10-12 breaths per minute, and observe a chest rise and fall in the patient [21]. In
the testing setup, markings on the bag provided guidelines for consistent hand placement,
breaths were delivered over a one second interval at a rate of 10 breaths per minute, in
accordance with American Heart Association resuscitation guidelines, and manikin chest
rise and fall was monitored.
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Figure 4.3. Manikin Resuscitation Set-Up. Left: Two-handed E-C Clamp. Right: One
handed E-C Clamp. For testing purposes, the configuration on the left was used.
Resuscitation Manikin and BVM Models
The Laerdal® SimMan® 3G manikin (Laerdal USA, Wappingers Falls, NY,
USA) and LLEAP software (version 6.6.0.3884) were utilized in the tidal volume
experiments. Manikin lung compliance was set to 0, which is recommended for
performing CPR. The manikin was programmed to have a heart rate of 20 beats per
minute and blood oxygen saturation of 79% to mimic conditions of a patient under
cardiac/respiratory arrest. The static airway compliance has been found to be lower than
that of human lungs due to the lung reservoir material not having the same elasticity as
human lung tissue [28]. For these research purposes, the lower lung compliance
illustrates a possible worst-case condition for a pulmonary fibrosis patient [29]. The
following BVM units were tested: Mask 1 (n=3), Mask 2 (n=2), Mask 1R (n=3), Mask
1PD (n=1), Mask 1FD (n=1), and Mask 1A (Table 2.1). Data was recorded over a period
of one minute to obtain a total of ten readings per BVM unit.
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4.3 RESULTS
4.3.1. Simulated Worst-Case Drying Time
The negative control samples, as expected, had RLU values greater than 100
(Table 4.2). The inoculum count (Appendix A.1) for this experiment was 1.27E5
CFU/mL of S. epidermidis. The negative control samples had 1.05E4 CFU/mL. All ‘dried
only’ samples had RLU values greater than 100, with the exception of one, indicating that
those surfaces still had sufficient levels of bioburden present. All ‘dried and reprocessed’
samples had RLU values close to 0 and exhibited no bacterial growth (Table 4.3).
Table 4.2. Simulated Worst-Case Drying Time ATP Results.
Sample

Dried only
Dried and
reprocessed

Negative
control
4 hours
8 hours
24 hours
4 hours
8 hours
24 hours

ATP Value (RLU)
Trial 1
Trial 2 Trial 3

Target
met?

281

249

330

N/A

175
194
153
1
0
0

148
77
252
3
0
0

n/a
n/a
n/a
1
0
0

No
No
No
Yes
Yes
Yes

Table 4.3. Simulated Worst-Case Drying Time Standard Plate Count Results.

Sample

Dried only

Negative
control
4 hours
8 hours
24 hours
4 hours

Log Reduction in Bacteria*
Trial
Trial 2
Trial 3
1
0

0

0

No bacteria growth on all
plates
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Target
met?
n/a

Yes

8 hours
Dried and
reprocessed
24 hours
*As calculated using Equation 4.1
4.3.2. Simulated Worst-Case Use Conditions
The negative control samples, as reflected in the average, had RLU values greater
than 100 (Table 4.4). This was the case for all negative control samples, which were all
above 163 RLU (Appendix A.4). The positive controls had an average RLU value of 1.4,
which met the disinfection target. The ‘With Organic Load’ masks had an average RLU
value of 1.6, which also met the disinfection target. Bacteria growth was observed for the
negative control, as expected, but not for the positive controls or ‘With Organic Load’
BVM (Table 4.5). The inoculum concentration (Appendix A.1)was 3.09E5 CFU/mL.
Table 4.4. Simulated Worst-Case Use Conditions ATP Results.
Sample
Negative
controls
Positive controls
With Organic
Load

Average ATP Value (RLU)

Target met?

672

N/A

1.40

Yes

1.60

Yes

Table 4.5. Simulated Worst-Case Use Conditions Standard Plate Count Results.
Sample

Log Reduction in Bacteria*
Trial 1
Trial 2
Trial 3

Negative
0
0
0
controls
Positive controls
No bacteria growth on all plates
With Organic
Load
*As calculated using Equation 4.1
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Target met?
N/A
Yes
Yes

4.3.3. Bag-Valve-Mask Functional Performance
The average tidal volumes and corresponding standard deviations (Appendix A.5)
fell within the target range of 400 to 700 mL for all masks except for the partially inflated
and fully deflated masks (Figure 4.4). Mask 1 (Appendix A.6) and Mask 1R (Appendix
A.7) had roughly a 2% difference in tidal volume. Mask 1A (Appendix A.9) and Mask 2
(Appendix A.8) were able to meet tidal volume targets as well. However, the Mask 1PD
and Mask 1FD (Appendix A.9) did not meet the minimum threshold for tidal volume
delivery. The partially deflated mask (Mask 1PD) produced tidal volumes above the
minimum threshold occasionally, but its average tidal volume was below the target range.
Most tidal volumes for Mask 1FD were nearly zero. Mask 1 and Mask 2 maintained an
average tidal volume within the range of 400 to 700 mL. Summarized tidal volume
statistics can be found in Table 4.6. There is no significant difference between the tidal
volume measured for masks used in a new condition or after 20 cycles of reprocessing
(Mask 1 vs. Mask 1R, t-test, p=0.479). There is also no significant difference between the
tidal volume measured for different masks used in a new condition (Mask 1 vs. Mask 2, ttest, p=0.900).
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Average Tidal Volume Comparison
800

Tidal Volume (mL)

700
600
500
400
300
200
100
0
BVM Mask Type
Mask 1

Mask 1R

Mask 2

Mask 1A

Mask 1PD

Mask 1FD

Figure 4.4. Average Tidal Volume Comparison.

Table 4.6. Average1,2 Tidal Volume Comparison.
Mask
Mean Tidal Volume (mL) (Standard Deviation), [Range]
604.7 (10.3), [597-616]
1
592.6 (24.4), [576-621]
1R
583.4 (121.8), [497-670]
2
559
1A
22
1FD
382
1PD
1
Data for Masks 1, 1R, and 2 represent the average of three trials of 10 repeated
measures of tidal volume
2
Data for Masks 1A, 1FD, 1PD represent the average of one trial of 10 repeated
measures of tidal volume
4.4 DISCUSSION
4.4.1. Simulated Worst-Case Drying Time
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The objective of this investigation was to study the impact of post-contamination
drying time on reprocessing protocol efficacy. No bacterial growth was observed for S.
epidermidis when drying times of 4 hours or more were used, which was the case for
both ‘Dried Only’ and ‘Dried and Reprocessed’ samples (Table 4.3). Previous work with
this reprocessing protocol showed that the protocol was able to meet disinfection targets
for Mask 3, which had a post-contamination drying time of 15 minutes (when bacteria
were confirmed to be alive) [8]. One conclusion that could be drawn from this is that the
protocol meets cleaning and disinfection targets, regardless of the drying time and vitality
of the S. epidermidis. However, it is important to note that the increased drying times
made the sampling of physical debris more challenging, which could have contributed to
the lack of observed bacterial growth. In regard to the variance in ATP values for the
‘dried only’ sample, this is likely due to the slightly uneven spread of the soil because of
PVC’s high surface tension and curvature of the mask the samples were cut from.
Reprocessing these BVM by soaking in the 0.5% sodium hypochlorite and 10%
detergent solutions was effective for achieving high-level disinfection, regardless of postcontamination drying time. Residual bioburden was present after extended drying times,
but there was an absence of detectable ATP after 20 minutes of exposure time to the
reprocessing solutions (Table 4.2). These findings were consistent with previous studies
[30, 31] investigating the consequences of soil drying on stainless steel instruments and
endoscopes due to delayed reprocessing from 30 minutes up to 24 hours. Alfa, et al.
found that using only a water flush during cleaning, in the absence of agitation or
scrubbing, was ineffective for removing dried soils and bacteria during endoscope
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reprocessing [31]. However, soaking for 20 minutes in glutaraldehyde was effective for
achieving high-level disinfection. Lipscomb, et al. found that any amount of postcontamination drying time of prion-infected tissue, even as little as 15 minutes, was
detrimental to the cleaning process [30]. This is likely due to the nature of the
contaminant, PrPSc (scrapie prion), an abnormal type of normal cellular protein. The
scrapie prion is highly aggressive in its surface adsorption abilities [32, 33]. It is apparent
that post-contamination time can negatively impact reprocessing protocol performance.
As demonstrated in the current study and work by Alfa, et al., bioburden can be
successfully removed if the right disinfectants are used for appropriate lengths of time.
4.4.2. Simulated Worst-Case Use Conditions
The simulated worst-case use conditions for organic load in the cleaning solutions
involved adding Artificial Mucus Soil to a sodium hypochlorite solution (5 000 ppm).
This investigation demonstrated that the bleach was effective in eliminating bioburden
from the masks, despite the presence of nearly 25% (vol/vol) added organic matter (Table
4.4 and Table 4.5). Bloomfield and Miller found decreased disinfection performance of
sodium hypochlorite (2,500 ppm) in the presence of human plasma and three bacterial
strains when 20% (vol/vol) plasma was added to the disinfectant solution (Table 4.7).
When this volume of plasma was added to the sodium hypochlorite, high level
disinfection was not achieved in two out of the three bacteria suspensions [34].
One study by Best et al. [35] examined the efficacy of a sodium hypochlorite
solution (5,000 ppm) with added organic matter in the form of tryptic soy broth (TSB)
and human serum (Table 4.7). Both suspensions and carrier surfaces were tested for the
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presence of bacteria [35]. Only the suspension achieved high-level disinfection when
TSB was the organic load involved. However, both the carrier surfaces and suspensions
failed to meet high-level disinfection when human serum was the organic load [35].
Although the bacteria-to-disinfectant ratio was smaller than that in the simulated worstcase use testing for the BVM, the contact time was ten-fold shorter in Best et al.’s study,
compared with the current BVM reprocessing study. These study conditions are not
identical to the current BVM reprocessing study, but results demonstrated that achieving
nearly a 6x reduction in bacteria under 10% (vol/vol) organic load is feasible with a 5,000
ppm sodium hypochlorite solution. In other studies, 5,000 ppm sodium hypochlorite
solutions have been widely proven and accepted for killing pathogenic material found in
bodily fluids such as blood, making them a suitable choice for achieving high-level
disinfection [36, 37].

Table 4.7. Organic Load Summary

Reference

Bleach
Concen.
(ppm)

Contact
Time
(min)

Organic
Load
(%
vol/vol)

Bacterial Species

Zemitis,
Harman,
Hargett, and
Weinbrenner
(current
study)

5 000

10

Artificial
Mucus Soil
(24%)

Staphylococcus
epidermidis
(ATCC12228)

1

TSB
(10%)

Listeria innocua
(LCDC 86-417)

Best et al.
[AV]

5 000*
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High-Level
Disinfection
Achieved?

Carrier
Surface
(PVC)

YES

Suspension

YES

Carrier
Surface
(Steel disc)

NO

Human
serum
(10%)

Suspension

NO

Carrier
Surface
(Steel disc)

NO

Suspension

YES

Pseudomonas
aeruginosa
(NCTC 6570)

Suspension

YES

Escherichia coli
(NCTC 8196)

Suspension

YES

Suspension

NO

Pseudomonas
aeruginosa
(NCTC 6570)

Suspension

NO

Escherichia coli
(NCTC 8196)

Suspension

YES

Listeria
monocytogenes
(LCDC 88-702
Staphylococcus
aureus
(NCTC 4163)

10

Bloomfield
and Miller
[AU]

Human
plasma
(10%)

2 500

Staphylococcus
aureus
(NCTC 4163)
10

Human
plasma
(20%)

*solution also contained 5% methylethanol
The two most important factors in disinfectant performance are
concentration and contact time [37]. The second study [34] used a sodium hypochlorite
concentration of 2,500 ppm, which is half the concentration of that used in the current
BVM reprocessing study and by Best et al [35]. However, its contact time was 10-fold
higher than that in the first study by Best et al. The sodium hypochlorite solution was
able to achieve high-level disinfection for all three bacteria species despite a significantly
lower disinfectant concentration [34]. One final key consideration is the type of bacteria
used, as some microorganisms are inherently more resistant to disinfectants than others.
All three studies discussed above used different bacteria species, which makes it
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challenging to equally compare disinfection outcomes. These studies illustrate the
interdependent relationship that variables such as disinfectant concentration, contact time,
bacteria, and organic matter presence have on disinfectant performance.
4.4.3. Bag-Valve-Mask Functional Performance
Level of reprocessing and presence of abrasion did not impede the BVM unit’s
ability to deliver adequate tidal volumes to the manikin. Even with abrasion damage, the
BVM was highly effective in delivering average tidal volumes within approximately 8%
to 4% of the new, unused masks (Masks 1 and 2, respectively). While the surface
abrasions may have impacted the seal, the 8% difference could be attributed to the human
operator, since hand placement, squeeze rate, and bag size have been found to heavily
influence tidal volume [27]. Human factor-related variables were constrained in testing as
much as possible by having care providers use the same hand placement during BVM use
and by using a metronome to time delivered breaths, but variability between bag squeeze
rates, even for the same care provider, is difficult to control. The reprocessed masks
(Mask 1R) achieved average tidal volumes of within <2% of the new, unused masks
(Masks 1 and 2).
However, punctures that caused mask deflation to any extent resulted in decreased
performance due to loss of conformity in the cuff. Based on these data, damage leading to
decreased functional performance are easily visualized and useful for screening masks
during reprocessing. One important point to highlight is that while the target tidal volume
range spans 400 to 700 mL, adequately ventilating the patient could require tidal volumes
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above or below this range. This is dependent on the patient’s physiopathology, as each
patient’s conditions before and during BVM intervention can vary [38].
4.4.4. Limitations
These studies provide a framework for simulating worst-case reprocessing
conditions and evaluating reprocessing protocol efficacy for the reuse of medical devices.
There are several limitations to note. Several assumptions were made regarding the
reprocessing conditions. First, ASTM Type I water was used to reduce likelihood of
water quality effects on the study, which was not the primary focus on the study. Water
quality may vary, especially in LMIC—understanding the water treatment in use is
crucial to the reprocessing of medical devices. S. epidermidis ATCC12228, grampositive, was chosen as the inoculum species. It is unknown how gram-negative bacteria
would respond to the same chemical treatment in the tested protocol. Finally, the selected
soiling conditions mimicked human mucus from a cystic fibrotic patient; in a clinical
setting, the BVM could be exposed to patient emesis and bacteria from improper
handling of the device and consequent contamination. The Laerdal® BAG® II BVM was
used in the protocol efficacy studies, which may not be fully representative of the other
BVM brands. While it has been shown that BVM functionality does not significantly
deviate across brands, the microbiological study results may not be generalizable to other
reprocessed BVM masks due to different mask materials, sizes, and geometries. Finally,
this study did not examine the effect of human factors, as there is likely variability
between users performing reprocessing of the BVM. All microbiological and tidal
volume work was performed by trained biomedical engineering students or medical staff.
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One final limitation to note is the sampling of bacteria discussed in Section 4.4.1.
No bacterial growth was seen for samples that were dried and reprocessed, as well as
samples that were dried but did not undergo reprocessing. The standard plate count
method was used to quantify bacterial growth, which involved sampling the area of
interest with a sterile cotton tipped swab and aseptically transferring the swab to a
dilution tube and vortexing for one minute. The challenge with the increased drying time
was that it became more difficult to physically remove debris from the sample coupon.
The ATP swabs were coated in a liquid solution, which made sampling of surfaces easier.
Visual inspection verified this, as the sampled side no longer had visible debris.
However, the dry cotton swab could only remove so much physical debris from the
sample surface without breaking due to the increased effort required during sampling.

4.5 CONCLUSION
These studies provided a holistic framework for validating reprocessing protocols
under simulated worst-case conditions. While prolonged post-contamination drying times
and high organic loads can negatively impact reprocessing protocol performance,
successful removal of bioburden is possible if the right disinfectants are used over
appropriate contact times. The sodium hypochlorite solution proved to be effective in
achieving high-level disinfection regardless of the simulated worst-case conditions.
Repeated reprocessing and presence of abrasion did not impede the BVM unit’s ability to
deliver adequate tidal volumes. Impactful future areas of investigation include examining
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the impact of human factors, specifically through usability studies, on user compliance
with the current BVM reprocessing protocol.
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CHAPTER FIVE
INFLUENCE OF HUMAN FACTORS ON REPROCESSING
5.1 INTRODUCTION
Human factors engineering (also known as usability engineering) involves the
study of human interactions with technology and the influence of user interface design on
these interactions [1]. In the reprocessing of medical devices, the aim of human factors
engineering is to demonstrate that a device can be safely and effectively reused. This
includes understanding who is performing reprocessing (referred to as the “user” in this
paper), under what conditions the reprocessing is being performed, and what the details
of the reprocessing procedure are [1]. Identification of critical tasks, which are tasks that
must be performed correctly for a process to be safe and effective, can be accomplished
through a task analysis [1]. This analytical approach divides processes into discrete
components so that user errors can be identified, as well as potential consequences of
those errors [1].
The FDA requires validation studies for cleaning and sterilization of medical
devices, with regulations covering both reusable devices and single-use devices [1-3].
Poorly written reprocessing instructions can hinder user compliance with those
instructions, especially for manual cleaning steps, which can increase the risk of
inadequate cleaning and negatively impact patient safety [4, 7, 8]. As described in
Chapters 2 and 3, a bleach-based reprocessing protocol taken from an urban Tanzanian
hospital successfully met disinfection targets for the bag-valve-mask (BVM), a
resuscitation device commonly reused in low-resource hospitals [5]. However, it is
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unknown how user variability contributes to the ability to achieve appropriate
disinfection for the BVM since the protocol has not been validated from a human factors
perspective. It is likely that the current reprocessing instructions may confuse someone
who is untrained or unfamiliar with reprocessing the device, as the written steps lack
clarity and do not provide detailed direction. Given that BVM are classified as semicritical reprocessed devices due to their contact with mucous membranes [6], they require
high-level disinfection (6-log reduction in bacteria) during reprocessing. Effective
disinfection can be compromised if reprocessing steps are omitted or completed
incorrectly.
The broad objective of this study is to design a usability study to assess protocol
compliance and task efficiency related to BVM reprocessing. This was accomplished by
1) creating a task analysis for BVM reprocessing, 2) defining key study output variables,
and by 3) establishing a usability study procedure that assesses defined study outputs.

5.2 MATERIALS AND METHODS
Bag-Valve-Mask Reprocessing Protocol
The bleach-based reprocessing protocol (Appendix C.1) described in Chapters 2-4
includes a 10-minute submersion of the device in a 0.5% sodium hypochlorite solution,
followed by a 10-minute submersion in non-enzymatic detergent (1:10 dish soap to
water), 1-minute submersion in ASTM Type I water, and 10-minute air dry:
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Soiled
Device

Soak in
0.5%
sodium
hypochlorit
10 min

Soak in
soapy
water
(1:10)
10 min

Submerge
in water

Air
dry

1 min

10 min

Figure 5.1. Reprocessing Protocol. General bleach-based decontamination protocol
utilized in an urban Tanzanian hospital.
Task Analysis
A task analysis (Appendix C.1) was developed for the bleach-based reprocessing
protocol, which is to be filled out by the researcher as they observe the study participant.
Sub-tasks for each of the nine main tasks in the protocol have the option to be ranked as
0, 1, or 2: 0 indicates the task was not completed at all, 1 indicates the task was
completed with some difficulty, and 2 indicates that the task was completed with ease.
Additionally, each task contained a designated space for general comments or
observations. The utility that this approach offers is a quantitative analysis of user
protocol compliance during reprocessing. While the task analysis provides some insight
into user behavior, other data collection methods are needed to gain a holistic
understanding of errors made during reprocessing and root causes.
Key Study Variables
This systematic documentation of reprocessing tasks and sub-tasks also led to the
identification of key study variables for BVM reprocessing. These variables can be
simplified into three categories (Table 5.1): level of protocol compliance, task efficiency,
and task difficulty level. Protocol compliance becomes a key variable when manual
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cleaning is involved in reprocessing. Extremely low compliance levels have been
demonstrated in endoscope reprocessing, which are the main cause of endoscopyacquired infections [7]. However, when the right protocol design changes are
implemented, compliance rates can significantly improve. This was demonstrated in a
study where improvements to endoscope reprocessing instructions using effective human
factors design principles nearly doubled protocol compliance [8]. In the current study, the
level of compliance is primarily assessed through a task analysis, as described in the
previous section.
Table 5.1. Key Study Variables.
Captured by
Category

Protocol
Compliance

Item

Camera

Device disassembly prior to cleaning

X

Soaking time of BVM components in
each solution

X

Number of steps and sub-steps that
were completed correctly

X

Full submersion of device in each
solution

X

Lid placement over bin in final step

X

Proper surgical glove disposal

Task
Efficiency

X

Surrounding surface cleaned with
bleach and cloth

X

Time it takes to complete each step

X

Number of times participant looks at
instructions for each step
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Observation

X

Participant method for time-keeping

Difficulty
Level

X

Participant facial expressions during
specific steps
Number and type of questions
participants asked

X
X

X

Task efficiency was selected as a variable of study due to the quick turnaround
times required in hospital reprocessing operations. This variable is measured by timing
each of the nine tasks in the protocol (Appendix C.2). Lastly, task difficulty is assessed
through a verbal questionnaire at the end of the study (Appendix C.2), in which responses
are recorded on a five-point Likert scale. This questionnaire addresses the how confident
the participant felt in their ability to reprocess the device, how thoroughly they thought
they cleaned the device, and how straightforward the protocol instructions appeared to
them. Additionally, participant facial expressions and comments are noted throughout the
study, which can confirm the difficulty level of the steps. These three key variables form
the framework for the usability study design.
Usability Study Participant Selection
Recruitment involves the posting of flyers on Clemson’s campus and sending emails to Clemson students and faculty. Those who wish to participate will be screened
over the phone or via e-mail, and their name, age, gender, phone number, and e-mail
address will be collected. Approximately 10-15 adults aged 18 years and older who can
read, write, and speak in English will be selected for participation. This number of
participants will allow the research team to reach a “saturation point” in data collection,
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where beyond this number, little to no new information about the process would be
gathered. The “saturation point” marks the end of the study and is determined when no
new insight is gathered in studying the behavior of one to two participants, consecutively,
compared to what was learned from the first few participants. Once this point has been
reached, an additional participant would add little to no value because researchers can
predict how future participants may behave with the sufficient level of information they
have already gathered. The participant questionnaire at the end of the study will gather
information on their level of formal lab training or experience working with chemical
handling or sanitation. The extent of formal liquids handling training and experience is
important to capture, as these factors could impact their ability to reprocess the BVM.
Usability Study Procedure
Each participant is assigned a participant ID, which will disassociate their name
with their data. Their data will only be available to the research team and will be stored
on a secure dual-authentication file-sharing and storage platform (Box, Box, Inc.,
Redwood City, CA). Key study output variables will be assessed using a combination of
video recording, direct observation, and in-person interviews. A video camera located
above the workspace will record the participant’s actions throughout the reprocessing
task without recording their face. Before starting, each participant will be given full detail
of the study, including potential risks (which there are none of). Upon signing the
informed consent form, participants will be tasked with reprocessing a fully assembled,
unused BVM at a designated workstation (Figure 5.2) with reprocessing instructions.
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Figure 5.2. Workstation Set-Up
Participants will put on surgical gloves before handling the BVM, treating the
device as if it has been used. On the workstation counter, three bins will be laid out side
by side labeled “Bleach”, “Soapy Water”, and “Clean Water.” Bleach was not used in
this study due to participant safety considerations, so the “Bleach” solution contains dyed
water. Additionally, the main focus of this study is on protocol compliance rather than the
ability of the protocol to meet disinfection targets; this will be addressed in a future study.
In the workspace, all necessary items (Figure 5.2) are available to the participant, which
include the same BVM unit from Chapter 4, all reprocessing chemicals, and surgical and
utility gloves as specified in the original reprocessing protocol (Table 5.2). Once the
participant has finished reprocessing the device, a verbal follow-up interview will be
completed by one researcher. Additionally, participant feedback for protocol
improvement will be requested.
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Table 5.2. Study Materials.

Item

Brand/Type

Quantity per
Participant

Bag-valve-mask unit

Laerdal® BAG II® and Adult Mask
#4
(referred to as Mask 1)

1

Liquid soap

Dawn® Ultra

Diluted 1:10
solution

Tap water

n/a

n/a

Simulated bleach
solution

Dyed water

5000 mL

Utility gloves

VersaPro™ Latex-Free

1 pair

Surgical gloves

VWR™ Microgrip® Purple Nitrile®

1 pair (multiple
sizes available)

Large bins and lids

Sterilite® (28 qt; 23” L, 16.25” W, 6”
H)

3

Wiping cloth

Vileda Professional® MicroTuff Base
Microfiber Cloth

1

Timer

n/a

1

Calculator

Texas Instruments

1

Pen and paper

n/a

1

Video camera,
memory card

n/a

1

Printed
decontamination
protocol

n/a

1
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5.3 CONCLUSION
While the bleach-based reprocessing protocol proved effective in eliminating
bioburden, it is unknown how human factors variables may impact the protocol’s ability
to meet disinfection targets as established by the FDA. As discussed in the previous
sections, study findings will include the identification of protocol steps with high
between-user variability and steps that cause confusion or mistakes. Ultimately, the
information gathered from the usability study will not only pinpoint variations in the
reprocessing of the BVM but will also inform improvement measures for the current
reprocessing protocol and aid in the development of future protocols. Current efforts
include recruiting potential study participants, pending IRB approval. Looking ahead to
the future of this body of work, the next phase may involve comparing the original
reprocessing protocol to an improved version and assessing the ability of each to meet
disinfection targets for the BVM.

80

REFERENCES
1) FDA: Applying Human Factors and Usability Engineering to Medical Devices, 2016.
UCM259760.
2) FDA Center for Devices and Radiological Health, Medical device use-safety:
Incorporating human factors engineering into risk management. Guidance for Industry
and FDA Premarket and Design Control Reviewers, July 2000.
3) Story, M. (2012). “FDA Perspectives on Human Factors in Device Development.
FDA.
4) Visrodia, K., Hanada, Y., Pennington, K.M., Tosh, P.K., Topazian, M.D., and
Petersen, B.T. (2017). Duodenoscope reprocessing surveillance with ATP testing and
terminal cultures: a clinical pilot study. Gastrointestinal Endoscopy,86(1):180-186.
5) Zemitis, S., Harman, M., Hargett, Z., and Weinbrenner, D. (2018). Single-Use Bag
Valve Masks: Evaluation of Device Design and Residual Bioburden Analytical Methods.
Journal of Biomedical Science and Engineering, 11(9):235-246.
6) Food and Drug Administration, Center for Devices and Radiological Health. Medical
Device User Fee and Modernization Act of 2002, Validation Data in Premarket
Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices, 2006.
7) Ofstead, C.I., Wetzler, H.P., Snyder, A.K. and Horton, R.A. (2010). Endoscope
reprocessing methods: a prospective study on the impact of human factors and
automation. Gastroenterology Nursing, 33:304-11.
8) Jolly, J.D., Hildebrand, E.A., and Branaghan, R.J. (2013). Better Instructions for Use
to Improve Reusable Medical Equipment (RME) Sterility. Human Factors, 55(2):397410.

81

CHAPTER SIX
ENGINEERING SIGNIFICANCE AND CONCLUSIONS
The broad objective of this thesis was to develop and validate a reprocessing
protocol for single-use devices (SUDs) commonly reused in low- and middle-income
countries (LMIC). In these studies, the bag-valve-mask (BVM) was the primary SUD of
interest. This objective was accomplished by fulfilling four aims: 1) document
reprocessing practices in a tiered healthcare system; 2) develop quantitative cleaning
validation methods for reprocessing; 3) evaluate reprocessing protocols in simulated
worst-case scenarios; and 4) define human factors affecting BVM reprocessing. Chapter
2 describes the findings that fulfill Aim 1, Chapter 3 addresses Aim 2, Chapter 4
addresses aim 3, and Chapter 5 addresses aim 4.
Aim 1: Document reprocessing practices in a tiered healthcare system.
Aim 1 was fulfilled using data acquired from in-person interviews with various
hospital personnel in Tanzania. These hospital interviews led to the identification of
commonly reused SUDs including electrosurgical instruments, bag-valve-masks, and
operating gowns. Most of the hospitals followed a generalized decontamination protocol
for SUDs without electrical components. None of the hospitals reported use of inspection
or screening processes prior to reuse and in many cases, SUDs were continually reused
until malfunctions occurred. This investigation reveals a clear need to develop and
validate SUD reprocessing procedures to ensure adequate decontamination of such
devices and reduce the risk of malfunction during use.
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The contributions from this aim provide a glimpse of medical device reprocessing
operations for a tiered healthcare system, for both urban and rural hospitals. This
systematic documentation of unregulated reprocessing practices (Table 2.3) is a first step
toward informing policies for safely reusing medical devices in hospitals throughout
Tanzania and training biomedical technicians/engineers to provide support for such
practices. Collaboration with Tanzanian universities is critical to furthering the
understanding of reprocessing practices across the region and in successfully developing,
validating, and implementing reprocessing protocols, as they are the ones who will
provide direct support to the hospital reprocessing operations and gain firsthand insight in
these areas.
Aim 2: Develop quantitative cleaning validation methods for reprocessing.
Aim 2 was fulfilled by investigating three different residual bioburden analytical
methods and assessing the efficacy of five reprocessing protocols applied to the BVM,
which were representative of the varied practices observed at LMIC hospitals. Simulated
worst-case contamination following an international standard for the validation of
reprocessing medical devices was used. The ATP detection and standard plate count
methods were found to be suitable for residual bioburden assessment due to their
accuracy and ability to produce quantifiable results. Both are widely used and accepted
for cleaning validation. The data support positive decontamination outcomes using the
bleach-based reprocessing protocol currently implemented in some Tanzanian hospitals.
Despite this, it was found that design features of the BVM mask presented challenges to
cleaning and drying for some decontamination protocols.
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Aim 3: Evaluate reprocessing protocols in simulated worst-case scenarios.
Aim 3 was fulfilled by investigating the impact of organic load and postcontamination drying time on reprocessing protocol efficacy, and the effects of repeated
use and reprocessing on BVM functional performance, to ensure safe BVM reuse. It was
found that the bleach-based reprocessing protocol was effective after a postcontamination drying time up to 24 hours, in highly alkaline pH solutions, and with
roughly 25% (vol/vol) added organic load (Artificial Mucus Soil). Repetitive
reprocessing and the presence of surface abrasion did not impede the BVM unit’s ability
to deliver adequate tidal volumes to the manikin.
Aim 4: Define human factors affecting BVM reprocessing.
Aim 4 was fulfilled by creating a task analysis for BVM reprocessing, defining
key study output variables, and by establishing a usability study procedure that assesses
defined study outputs. Three key variables of interest were identified for the usability
study: protocol compliance, task efficiency, and task difficulty level. The task analysis
detailed main tasks and sub-tasks for reprocessing of the BVM and provided a
quantitative way to assess user protocol compliance. Data collection methods included inperson Likert scale questionnaires, direct observation, and video recording. Ultimately,
the information gathered from the usability study will not only pinpoint variations in the
reprocessing of the BVM but will also inform improvement measures for the current
reprocessing protocol and aid in the development of future protocols.
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Conclusion
In the broader scheme of reprocessing, this body of work provides a
comprehensive framework for validating reprocessing protocols for single-use medical
devices while keeping resource constraints in mind. Hospitals in low-resource areas can
follow a similar approach to validate and establish reprocessing protocols for the reuse of
their devices. While the validation work described in this thesis may be useful to LMIC
hospitals, it can be extended beyond the low-resource setting. This body of work utilized
standards and accepted practices that are consistent with cleaning validation required by
the FDA and supported by AAMI [2-5]. For example, the experimental design and
selection of clinically relevant soil for the validation studies was heavily influenced by
AAMI guidelines for cleaning reusable medical devices [1]. Disinfection targets for the
BVM were based off the Spaulding Classification outlined in FDA documents [2]. The
worst-case soil mixture was prepared according to an international standard (ASTM) for
validation of cleaning methods for reusable medical devices [3]. Finally simulated worstcase functionality testing was carried out in efforts to define safe limits of device reuse,
as required by the FDA in validation data in 510(k)s for reprocessed SUDs [4].
Certain device design features can negatively impact reprocessing, as seen in
Chapters 2 and 3. Devices with electrical components were not able to undergo the
general decontamination protocol due to their inability to be submerged in disinfectant
(Chapter 2). Consequently, these devices were either thrown out after malfunctioning or
were attempted to be cleaned through means that may not achieve the required high-level
disinfection. Several design features of the masks used in Chapter 3 were considered
reprocessing challenges, including small crevices near the valve attachment, contours on
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the outside surface, and tight folds inside the mask. These features proved to be
opportunistic areas for bacteria and physical debris buildup and hampered the ability of
the alcohol wipe protocol to achieve high-level disinfection. Design features like these
can become zones of bioburden entrapment and should either be avoided in the design of
reusable devices or given more attention during reprocessing [5].
To conclude, risks and benefits should be appropriately weighed when
considering whether a device should be used multiple times or just once. Risk of
infection is an important consideration in the reuse of medical devices. One could pose
the case that the risk of serious infection transmission with the bag-valve-mask is low
because it is not in contact with sterile body cavities. As demonstrated in Chapters 2 and
3, if properly reprocessed, the BVM will be appropriately disinfected and functionally
safe for the next user. However, in cases where the patient has a significant risk of being
exposed to highly pathogenic agents (such as prions), having a disposable device or
disposable component to the device may be safer for the patient and healthcare personnel.
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Appendix A
Raw Data for Statistical Analysis
Table A.1. Inoculum Counts for Microbiological Studies
Study
Residual Bioburden Analyses (Chapter 3)
Simulated Worst-Case Drying Time
(Chapter 4)
Simulated Worst-Case Use Conditions
(Chapter 4)

Inoculum Count
1.22E7-2.61E7 CFU/mL
1.27E5 CFU/mL
3.09E5 CFU/mL

Table A.2. Residual Bioburden Analyses Standard Plate Count Results Trial 1. CFU
counts for the bag-valve-mask for trial 1 are listed in the table below.
Concentration
Plate
Count Count Avg.
[bacteria/swabDilution
1
2
Count
mL]
Negative
Control
Water
Rinse
Alcohol
Wipe
Soap
and
Bleach
Positive
Control

Log
bacteria

Log
reduction

0

178

184

181

181000000

8.3

0

0

32

37

34.5

34500

4.5

3.7

1

0

0

0

0

0

8.3

1

0

0

0

0

0

8.3

1

0

0

0

0

0

8.3
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Table A.3. Residual Bioburden Analyses Standard Plate Count Results Trial 2. CFU
counts for the bag-valve-mask for trial 2 are listed in the table below.
Concentration
Plate
Count Count Avg.
[bacteria/swabDilution
1
2
Count
mL]
Negative
Control
Water
Rinse
Alcohol
Wipe
Soap
and
Bleach
Positive
Control

Log
bacteria

Log
reduction

0

146

144

145

14500000

7.2

0

0.01

49

96

72.5

7250

3.9

3.3

0.01

49

96

72.5

7250

3.9

3.3

1

0

0

0

0

0

7.2

1

0

0

0

0

0

7.2

Table A.4. Simulated Worst-Case Use Conditions ATP Results.
ATP Value (RLU)
Replicate
2
3
4

5

668

638

709

--

--

2

4

0

0

2

1

1

1

2

2

Sample
1
Negative
controls
Positive controls
With Organic
Load

Table A.5. Summary: Average Tidal Volume Data. Tidal volumes were recorded for
each mask condition during functionality testing.
Mask
Condition
1
1R
2
1A
1FD
1PD

Average Tidal Volume (mL)
Mask Replicate
1
2
3
616.3
601.3
596.5
580.9
576.3
620.6
669.5
497.3
559.4
15
391.5
-
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Mean Tidal Volume (mL)
(Standard Deviation),
[Range]
604.7 (42.7), [526-703]
592.6 (60), [466-696]
583.4 (108.1), [434-739]
559.4 (62.3), [430-642]
14.6 (51.3), [0-199]*
391.5 (68.3), [217-458]*

Table A.6. Raw Tidal Volume Data: Mask 1. Tidal volume data was collected for the
new, unused Laerdal® bag-valve-mask.

1
657
602
565
588
595
623
638
703
650
542

Tidal Volume (mL)
Mask Replicate
2
526
657
608
591
612
630
539
596
640
614

3
599
615
635
610
600
610
541
569
527
659

Table A.7. Raw Tidal Volume Data: Mask 1R. Tidal volume data was collected for the
reprocessed (n=20 cycles) Laerdal® bag-valve-mask.

1
579
466
470
584
640
626
547
565
640
692

Tidal Volume (mL)
Mask Replicate
2
644
546
560
608
548
513
589
595
578
582
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3
509
635
547
654
673
593
672
696
636
591

Table A.8. Raw Tidal Volume Data: Mask 2. Tidal volume data was collected for two
replicates of a new, unused Ambu® SPUR® II bag-valve-mask.
Tidal Volume (mL)
Mask Replicate
1
716
739
713
704
679
687
651
565
586
655

2
464
453
443
434
457
470
550
522
513
667

Table A.9. Raw Tidal Volume Data: Destructed Masks. Tidal volume data was
collected for one abraded mask, one fully deflated mask, and one partially deflated mask.

1A
513
430
569
585
590
593
622
517
642
533

Tidal Volume (mL)
1FD
0
20
0
0
0
0
0
199
0
0
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1PD
432
389
458
419
398
378
304
404
424
217

Appendix B
Test Conditions and Protocols

In biological safety cabinet,
sterile scissors are used to
aspetically transfer one S.
epidermidis loop to bottle of
98 mL sterile tryptic soy broth
(1:49 dilution).

Lid is secured on
bottle and contents
gently agitated
manually for 15
seconds. Lid
immediately
loosened.

Tryptic soy
broth + S.
epidermidis
loop incubated
for 24 hours at
37°C.

Figure B1. Staphylococcus epidermidis preparation. A 2% aseptic transfer of one
ATCC 12228 Culti-Loop™ (Thermo Scientific™) into sterile tryptic soy broth was made
and incubated for 24 hours at 37°C.

Plates are removed from
incubator and inverted
(if not inverted already)
so that the bottom of the
petri dish is facing up.

Count CFUs
(individual white,
round dots in the
case of S.
epidermidis) with
permanent marker
on every plate that
exhibited growth.
Countable range is
30-300.

To determine the
bacteria count
(per mL) for the
specimen, take
the plate count
average for that
dilution and
divide it by the
dilution
concentration.

Figure B2. Standard Plate Count Protocol. The standard plate count method was used
to determine the number of colony-forming units (CFU) during microbiological testing.
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After removing test swab cap, one site
(varying in size depending on study) is
tested from each sample using the
provided ATP test swab. Cap is placed
on swab until handheld device is
powered on and ready for measurement.

Snap valve is broken and
squeezed twice to release
liquid inside test swab.
Test swab is gently shaken
for 5 seconds and then
inserted into the ATP
handheld device.

'OK' button is
pressed on
handheld
device and an
ATP reading
is given in 15
seconds.

Figure B3. Ruhof ATP Complete® Protocol. ATP testing determined the presence of
adenosine triphosphate and followed manufacturer’s instructions, which are detailed in
the figure below.
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Bleach pH Change (With and Without Added Organic Matter)
11.5

y = -0.0059x + 11.313
R² = 0.9954

11
10.5

pH

10
9.5
9
8.5
8
-3

2

7

12

17

22

27

32

37

42

Time (minutes)
30 mL, 10 dips (1)

30 mL (2)

60 mL, 20 dips (1)

100 mL, 33 dips (1)

Bleach (no soil) (2)

Linear (Bleach (no soil) (2))

Figure B4. Bleach pH Change Over Time. Fresh 0.5% sodium hypochlorite solutions
were prepared, and the pH was monitored over time as various amounts of organic matter
were added. This was done to find stable pH decay after the addition of organic matter
for the protocol efficacy study. After roughly 10 minutes after adding organic matter
(Artificial Mucus Soil), pH decreased at a steady rate.
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Table B1. Artificial Mucus Soil Recipe. Test soil recipe taken from the ASTM F3208
standard. Mucin was added to water and stirred at approximately 380 rpm for 4-5 hours
or longer. The remaining ingredients were added while the stir bar was in the mixture.
After removal from stirrer, final volume of water was added. Finally, pH was adjusted
using 0.1M HCl to 6.75.
*Used 1.5 1-mL vials due to high material costs and resource constraints

Component

Amount (Original)

Amount (for ~ 1L)

Pig mucin

100 mg

1,1230 mg

Casein hydrolysate

500 mg

5,650 mg

Sodium chloride (NaCl)

500 mg

5,400 mg

Diethylenetriaminepentaacetic
acid (DPTA)

0.59 mg

6.67 mg

Water

80 mL

901.4 mL

Potassium chloride (KCl)

500 mg

5,650 mg

Salmon sperm DNA

140 mg*

~1.5 mL*

Egg yolk emulsion

232 mg

5.14 mL

Water (final addition)

20 mL

226 mL
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Appendix C
Human Factors Documents
Table C.1. Task Analysis for Usability Study.
Scores will be given as follows:
0- participant fails to properly complete step
1- participant completes step, but with some difficulty
2- participant completes step with ease

1

Put on
appropriate PPE
(gloves, safety glasses).

Notes

Score

2
1.
Make 0.5%
bleach
solution

Correctly measure out
solutions for correct
percentage (using 1/10
dilution, or 1 part
“bleach” + 9 parts
water) and places in
provided containers.

Notes

Score

Notes
3

Mix the measured
solutions.
Score

Section debrief notes:
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Participant
1

2

3

1

Ensure
appropriate PPE
(gloves, safety
glasses...may have
already completed this
in previous step).

Notes

Score

2

Read the instructions in
entirety.

2. Prepare for
decontaminat
ion

Notes

Score

3

Locate the necessary
components (BVM,
clock, bins).

Notes

Score

Section debrief notes:

3. Submerge
BVM in
bleach
solution

1

Place BVM in correct
bin.

Notes

Score
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2

Ensure the BVM is
fully submerged in bin.

Notes

Score

3

Time the step to ensure
it is submerged for 10
minutes.

Notes

Score
Section debrief notes:

1

Take off old gloves and
dispose of them
properly.

Notes

Score
4. Prepare to
wipe
contaminated
surfaces with
cloth

2

Cover the
decontamination
container.

Notes

Score

3

Put on new gloves and
ensure a cloth is
soaking in a chlorine
solution for future
steps.
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Notes

Score
Section debrief notes:

1

5. Wipe
surfaces with
cloth

2

Open the
decontamination
container, ensuring the
BVM stays submerged
if cloth was placed in
bin. If not placed in the
bin, make sure the cloth
was soaked in chlorine
solution.

Fully wipe off the
surfaces the BVM
touched with the cloth.

Notes

Score

Notes

Score

Notes
3

Switch gloves properly.

Score
Section debrief notes:

6. Remove
BVM from
chlorine
container

1

Ensure new gloves
have been put on after
previous step (may
have already
completed)
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Notes

Score

2

Remove BVM from the
bleach solution
container

Notes

Score

3

Move the BVM to the
soapy solution,
ensuring no spilling
while
removing/transport.

Notes

Score
Section debrief notes:

1

Prepare soap solution
(use dilution of 1/11, or
1 part soap to 10 parts
water) in provided
container.

Notes

Score
8. Place
BVM
in soapy
water
solution

2

Place BVM in soapy
container for 10
minutes.

Notes

Score

Section debrief notes:
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1

Remove BVM unit
from soapy water and
transfer to clean water
container.

Notes

Score
9. Finish
disinfection
process for
BVM
2

Dry the device (not
specified in protocol-drying with lint-free
clean cloth soaked in
alcohol is best,
followed by air dry).
No need to “send to
sterilization” for this
device.

Section debrief notes:
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Notes

Score

Figure C.1. Bleach-Based Reprocessing Protocol. The following protocol is used in the
urban Tanzanian hospitals for the general decontamination of devices without electrical
components.
Preamble: Decontamination is the process that makes inanimate objects safer to handle
by staff before cleaning (i.e. inactivates Hepatitis B Virus, Hepatitis C Virus, and Human
Immunodeficiency Virus, and reduces the number of microorganisms but does not
eliminate them)
Policy Statement: All medical staff must decontaminate soiled instruments before
cleaning.
Decontamination solutions used: 0.5 % chlorine, liquid soap, tap water
Procedure:
1. Decontamination is the first step in handling used instruments and other items that
have been in contact with blood or body fluids.
2. Leave surgical or examination gloves on post procedure or put on utility gloves.
3. Place all instruments in 0.5% chlorine solution for 10 minutes for
decontamination. Immediately after completing the procedure, make sure that all
devices are submerged in the solution.
4. Remove surgical gloves by turning inside out and dispose of gloves in a leakproof waste container or heavy-duty plastic bag.
5. Cover the decontamination container.
6. Using utility gloves, clean all surfaces contaminated during procedure by wiping
them with a cloth soaked in 0.5% chlorine solution.
7. Remove instruments from 0.5% solution after 10 minutes and immediately take
them for cleaning.
8. Place the instruments in the container with soapy water that has been diluted 1:10
for 10 minutes.
9. Then remove the instruments and dip in the container with clean water rinse, then
dry and send for sterilization.
Guidelines:
● Change the decontamination solution daily, or more often if necessary (change
when it becomes dirty).
● Use plastic non-corrosive containers for decontamination to prevent dulling of
sharps (e.g. scissors).
● Do not soak instruments that are not 1.10% stainless steel even in plain water.

103

Table C.2. Protocol Step Timing.
Step

Time

Start time:
1

Participant finishes reading
protocol
Participant places BVM in bleach
bin

2
Participant removes BVM from
bleach bin
3

Participant wipes surrounding
surfaces with bleach-soaked cloth
Participant places BVM in soapy
water bin

4
Participant removes BVM from
soapy water bin
Participant places BVM in
deionized water bin
5

Participant removes BVM from
deionized water bin and places
out to dry

6

End Time:
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Duration of Step

Figure C.2. Follow-Up Interview Questions.
Please rate the following statements on a scale of 1 to 5, 1 being strongly disagree and 5
being strongly agree. Example:
1
2
3
4
5
◯
◯
◯
◯
◯
Strongly disagree Disagree
N/A
Agree
Strongly agree
1. This decontamination process was straightforward and easy to understand.
◯
◯
◯
◯
◯
Strongly disagree Disagree
N/A
Agree
Strongly agree
(If participant chooses value of 2 or less OR 4 or more, ask them why)
2. I was confident in my ability to follow the protocol.
◯
◯
◯
◯
◯
Strongly disagree Disagree
N/A
Agree
Strongly agree
(If participant chooses value of 2 or less OR 4 or more, ask them why)
3. I was able to clean the device thoroughly.
◯
◯
◯
◯
◯
Strongly disagree Disagree
N/A
Agree
Strongly agree
(If participant chooses value of 2 or less OR 4 or more, ask them why)
4. Is there anything you would change about this protocol to improve your
experience?

5. To what extent have you had experience cleaning something like this (i.e. in a job
at a restaurant/babysitting, wet lab experience in college courses, handling of liquid
chemicals, etc.)? If so, explain.
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Table C.3. Researcher Response Guide. Due to the nature of the study, the research
team can only answer certain questions. These questions and appropriate responses are
listed in this table.
Question from
Participant
Where is [insert
item]?

Question Intent

Response

Seeking Clarity (location of [Show participant where an item is
an item if they can’t find it)
if they cannot find it]

Does this look
right?

Verifying Correct
Execution of Step

We cannot provide any
information on that. [Encourage
participant to continue in
completing step & moving
forward]

Can I use my
phone to keep
time? OR Do you
have something I
can use to keep
time?

Verifying Acceptable
Action

(A clock will be visible in the
room and a timer is available upon
request) Yes!

Seeking Clarity (Not in
protocol)

We cannot provide any
information on that. [Encourage
participant to continue in
completing step & moving
forward]

Seeking Clarity (safety)

This solution is not bleach. It is
similar but should not damage
your clothes or yourself.

How long does
the cloth need to
soak?

Seeking Clarity (Not in
protocol)

We cannot provide any
information on that. [Encourage
participant to continue in
completing step & moving
forward]

How do I make
the soapy solution
OR how much
water and soap
am I supposed to

Seeking Clarity (not a
specific amount in
protocol)

We cannot provide any
information on that. [Encourage
participant to continue in
completing step & moving
forward]

How do I take this
apart? OR Do I
have to take this
apart?
Will the bleach
solution damage
my clothes or
skin?
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use?

Seeking Clarity (confusion
over extent of study)

We cannot provide any
information on that. [Encourage
participant to continue in
completing step & moving
forward]

Seeking Clarity (Protocol)

We would like the opportunity to
revisit your study, but we do not
want to collect your personal
information, including your face.

Is this done? OR
What is next?

Verifying Completion

We cannot tell you any
information on that. If you believe
you are done, please tell us that
you are finished.

What is a Bag
Valve Mask
(BVM)?

Seeking Clarity (unknown
device to them)

A Bag Valve Mask is used to help
patients breathe when they are not
or having major complications.

Am I supposed to
wait exactly 10
minutes for each
step?
Why are you
recording my
hands but not my
face?
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